<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>297</serviceExecutionTime><Trial id="167464"><TitleDisplay>Sorafenib Tosylate, Cisplatin and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</TitleDisplay><TitleOfficial>A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02035527</Identifier><Identifier type="Organisational Study">OSU-13141</Identifier><Identifier type="Secondary Organisational">NCI-2013-02086</Identifier></Identifiers><Indications><Indication id="307">Squamous cell carcinoma</Indication><Indication id="3673">Metastatic head and neck cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>sorafenib</Name><Drug id="29831">sorafenib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2953">docetaxel</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1041750">National Comprehensive Cancer Network</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1042263">Ohio State University Comprehensive Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="29831">sorafenib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1041750">National Comprehensive Cancer Network</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1042263">Ohio State University Comprehensive Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2953" type="Drug"><TargetEntity id="140605" type="siDrug">Docetaxel</TargetEntity></SourceEntity><SourceEntity id="29831" type="Drug"><TargetEntity id="301618" type="siDrug">Sorafenib</TargetEntity></SourceEntity><SourceEntity id="1041750" type="Company"><TargetEntity id="5000730188" type="organizationId">National Comprehensive Cancer Network Inc</TargetEntity></SourceEntity><SourceEntity id="1042263" type="Company"><TargetEntity id="5035525936" type="organizationId">Ohio State University Comprehensive Cancer Center-Arthur G James Cancer Hospital and Solove Research Institute</TargetEntity></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"></TargetEntity><TargetEntity id="D002294" type="MeSH"></TargetEntity><TargetEntity id="-1612557995" type="omicsDisease"></TargetEntity><TargetEntity id="676" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1722" type="Action"><TargetEntity id="1103" type="Mechanism">VEGFR Inhibitors</TargetEntity><TargetEntity id="1619" type="Mechanism">Anti-VEGF</TargetEntity><TargetEntity id="1788" type="Mechanism">Vascular Endothelial Growth Factor (VEGF) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="4542" type="Action"><TargetEntity id="1212" type="Mechanism">Raf Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4548" type="Action"><TargetEntity id="2892" type="Mechanism">Raf kinase B Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4550" type="Action"><TargetEntity id="2963" type="Mechanism">Raf kinase C Inhibitors</TargetEntity></SourceEntity><SourceEntity id="48492" type="Action"><TargetEntity id="1651" type="Mechanism">PDGFRbeta Inhibitors</TargetEntity><TargetEntity id="1831" type="Mechanism">Anti-CD140b (PDGFRbeta)</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1042263">Ohio State University Comprehensive Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1041750">National Comprehensive Cancer Network</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1722">VEGF receptor antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="4542">Raf protein kinase inhibitor</Action><Action id="4548">Raf B protein kinase inhibitor</Action><Action id="4550">Raf 1 protein kinase inhibitor</Action><Action id="48492">PDGF receptor beta antagonist</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>3</PatientCountEnrollment><DateStart>2014-04-14T00:00:00Z</DateStart><DateEnd type="actual">2017-04-20T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:43:19Z</DateChangeLast><DateAdded>2014-01-20T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>Panos.Savvides@osumc.edu</Email><Name>Panayiotis Savvides, MD PhD MPH</Name><Phone>614-293-9868</Phone></Contact><Contact type="Scientific contact"><Affiliation>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center; Columbus; Ohio; 43210; United States</Affiliation><Name>Bo Chao</Name></Contact><Contact type="Scientific contact"><Affiliation>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center; Columbus; Ohio; 43210; United States</Affiliation><Name>Maura Gillison</Name></Contact><Contact type="Scientific contact"><Affiliation>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center; Columbus; Ohio; 43210; United States</Affiliation><Name>Pawan Kumar</Name></Contact><Contact type="Scientific contact"><Affiliation>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center; Columbus; Ohio; 43210; United States</Affiliation><Name>Panayiotis Savvides</Name></Contact><Contact type="Scientific contact"><Affiliation>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center; Columbus; Ohio; 43210; United States</Affiliation><Name>Theodore Teknos</Name></Contact><Contact type="Scientific contact"><Affiliation>Ohio State University Comprehensive Cancer Center</Affiliation><Name>Matthew Old, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have histological or cytological proof of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) of any primary site, including unknown primary cancers of the head and neck excluding nasopharyngeal carcinoma of histologic types World Health Organization (WHO) 2 or 3, paranasal sinuses primary or squamous cell carcinoma that originated in the skin&lt;/li&gt;&lt;li&gt;Patients must have SCCHN that is either:&lt;ul&gt;&lt;li&gt;Recurrent, judged incurable by surgery or (chemo)radiation or&lt;/li&gt;&lt;li&gt;Metastatic&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients must not have received prior chemotherapy for recurrent or metastatic disease&lt;/li&gt;&lt;li&gt;Patients may have received one regimen of induction, concomitant chemoradiotherapy and/or adjuvant chemotherapy as part of their initial treatment with curative intent, which must have been completed for a minimum of 4 months prior to study treatment and patient must have been progression-free for at least 4 months since completion of treatment with curative intent&lt;/li&gt;&lt;li&gt;Patients with recurrent disease are allowed a maximum of one prior radiation therapy regimen, either curative or palliative&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1&lt;/li&gt;&lt;li&gt;Patients must have measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) criteria; patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as&amp;gt;/= 20 mm with conventional techniques or as &amp;gt;/= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam&lt;/li&gt;&lt;li&gt;Absolute neutrophil count (ANC) 1500/mm3&lt;/li&gt;&lt;li&gt;Platelet count 100,000/mm3&lt;/li&gt;&lt;li&gt;Creatinine within normal limits (WNL), or creatinine clearance&amp;gt;/= 60 ml/min, based on the Cockroft-Gault formula&lt;/li&gt;&lt;li&gt;Total bilirubin WNL&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)&amp;lt; twice the upper normal limit&lt;/li&gt;&lt;li&gt;Patients must have controlled blood pressure (150/90 mmHg) prior to initiation of treatment&lt;/li&gt;&lt;li&gt;Women must not be pregnant or breast feeding; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of&lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; administration&lt;/li&gt;&lt;li&gt;Patients must be human immunodeficiency virus (HIV)-negative&lt;/li&gt;&lt;li&gt;Ability to understand and the willingness to sign a written informed consent document&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who have had chemotherapy or radiotherapy within 3 months prior to entering the study&lt;/li&gt;&lt;li&gt;Patients who are receiving any other investigational agents&lt;/li&gt;&lt;li&gt;Patients with known brain metastases will be excluded from this clinical trial&lt;/li&gt;&lt;li&gt;History of allergic reactions attributed to compounds of similar chemical or biological composition to&lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;, cisplatin&lt;/li&gt;&lt;li&gt;Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension (systolic pressure&amp;gt; 140 mmHg or diastolic pressure &amp;gt; 90 mmHg [National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version  4.0] on repeated measurement) despite optimal medical management&lt;/li&gt;&lt;li&gt;Evidence or history of bleeding diathesis or coagulopathy&lt;/li&gt;&lt;li&gt;Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 &gt;/= grade 2  within 4 weeks before randomization; any other hemorrhage/bleeding event of NCI-CTCAE v4.0 &gt;/=  grade 3 within 4 weeks before randomization&lt;/li&gt;&lt;li&gt;Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within 6 months of informed consent&lt;/li&gt;&lt;li&gt;Subjects who have used strong cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort [Hypericum perforatum], or rifampin [rifampicin], and/or rifabutin) within 28 days before randomization&lt;/li&gt;&lt;li&gt;Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for &gt; 3 years before randomization are allowed; all cancer treatments must be completed at least three years prior to study entry (ie, signature date of the informed consent form)&lt;/li&gt;&lt;li&gt;History of organ allograft; (including corneal transplant)&lt;/li&gt;&lt;li&gt;Any malabsorption condition&lt;/li&gt;&lt;li&gt;Inability to comply with the protocol&lt;/li&gt;&lt;li&gt;Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of dose-limiting toxicity (DLT) as graded according to the NCI-CTCAE v4.0 (phase I): a DLT will be considered a grade 3 non-hematological toxicity or grade 4 hematological toxicity that are probably or definitely related to treatment and result in treatment delay of &gt; 14 days</Description><Timeframe>Day 21 of course 1</Timeframe></Measure><Measure><Description>Progression-free survival (PFS) (phase II): PFS will be estimated using the Kaplan-Meier method</Description><Timeframe>Time of enrollment to the date of progression diagnosis or death, assessed up to  4 weeks after completion of study treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Biomarker levels: biomarkers from tissue and blood samples will be evaluated and correlated with outcome parameters. Correlative biomarkers will be analyzed using mixed model for repeated measurement to account for the association of measures overtime from the same patient</Description><Timeframe>Up to 42 days</Timeframe></Measure><Measure><Description>Incidence of toxicities, graded according to NCI-CTCAE version 4.0</Description><Timeframe>Up to 4 weeks after completion of study treatment</Timeframe></Measure><Measure><Description>Overall survival (OS): OS will be estimated using the Kaplan-Meier method</Description><Timeframe>Up to 4 weeks after completion of study treatment</Timeframe></Measure><Measure><Description>Response rate evaluated by RECIST v1.1</Description><Timeframe>Up to 4 weeks after completion of study treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase I/II trial was to determine the side effects and the best dose of &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib tosylate&lt;/ulink&gt; and      &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; when given together with cisplatin and to see how well they work in treating      patients with recurrent or metastatic squamous cell carcinoma of the head and neck. &lt;/para&gt;&lt;para&gt;The primary objectives of the study were: &lt;br/&gt;To define progression-free survival of patients with recurrent/metastatic squamous cell carcinoma treated with cisplatin/docetaxel/sorafenib (sorafenib tosylate) (CDS) combination chemotherapy (Phase II).&lt;br/&gt;To determine the optimal doses of cisplatin/docetaxel/sorafenib to be used in the phase II portion of the trial (Phase I).&lt;/para&gt;&lt;para&gt;The secondary objective was to determine overall survival, response rate, conduct biomarker studies and toxicities.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib tosylate&lt;/ulink&gt; orally twice-daily on days 1 to 14 of course 0. Beginning in course 1, patients would receive &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib tosylate&lt;/ulink&gt; (200 or 400 mg) po bid on days 1 to 21, &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (50 or 75 mg/m2) iv over 1 h on day 1, and cisplatin (75 mg/m2) iv over 1 h on day 1.Treatment      would repeat every 21 days for up to six courses in the absence of disease progression or      unacceptable toxicity. Patients would then receive &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib tosylate&lt;/ulink&gt; orally twice-daily in the absence of      disease progression or unacceptable toxicity.      Correlative studies would be performed and a total of three biopsies (blood and tumor samples) would be obtained in consenting patients. Pre-treatment biopsy to establish diagnosis and baseline data and research biopsy would be obtained at the end of a 2-week period of &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib tosylate&lt;/ulink&gt; monotherapy just prior to administration of cycle 1 with cisplatin and &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;. Research biopsy would also be obtained at the end of two chemotherapy cycles. After completion of study treatment, patients would be followed up for 4 weeks [&lt;ulink linkType="Reference" linkID="1586476"&gt;1586476&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43210</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Head and neck tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3764">Subjects with Laryngeal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3774">Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3777">Subjects with Specific Histological Sub-type of HNC</PatientSegment><SubSegments><SubSegment id="3778">Subjects with squamous cell carcinoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3804">Subjects with Relapsed/Recurrent Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7278">Subjects with Oral Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7279">Subjects with Nasal Cavity and Paranasal Sinus Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7280">Subjects with Salivary Gland Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7281">Subjects with Pharyngeal Cancer</PatientSegment><SubSegments><SubSegment id="7282">Subjects with nasopharyngeal cancer</SubSegment><SubSegment id="7283">Subjects with oropharyngeal cancer</SubSegment><SubSegment id="7284">Subjects with hypopharyngeal cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10290">Subjects with TNM Stage IV Head and Neck Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02035527</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Head and neck tumor" id="7256"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7311"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7313">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Head and neck tumor" id="7244"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7263"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7311"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7335"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Head and neck tumor" id="4359"><Criterion>Subjects with Oral Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4360"><Criterion>Subjects with Nasal Cavity and Paranasal Sinus Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4370"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4386"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4396"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4397">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Head and neck tumor" id="4398">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4414"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4415">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Head and neck tumor" id="4416">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Head and neck tumor" id="4417">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4425"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4426">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Head and neck tumor" id="4427">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4451"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4793"><Criterion>Subjects with Specific Histological Sub-type of Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4794">Subjects with squamous cell head and neck carcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4960"><Criterion>Subjects with Salivary Gland Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="7086"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="7093"><Criterion>Subjects with Pharyngeal Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4361">Subjects with nasopharyngeal cancer</SubCriterion><SubCriterion disease="Head and neck tumor" id="4362">Subjects with oropharyngeal cancer</SubCriterion><SubCriterion disease="Head and neck tumor" id="4363">Subjects with hypopharyngeal cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="7094"><Criterion>Subjects with Laryngeal Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="34017"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4419">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Head and neck tumor" id="5712"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5744"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5751"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5771"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="8712">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5777"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5779">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Head and neck tumor" id="5781">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-04-20T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.58 Months</EnrollmentPeriod><EnrollmentRate>0.24 Patients/Month</EnrollmentRate><DateFirstReceived>2014-01-10T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-05-14T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-05-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="255102"><TitleDisplay>Prospective clinical and pharmacoeconomic outcomes study of different first-line antiretroviral treatment strategies</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">DRKS00006321</Identifier><Identifier type="Secondary Organisational">14-5847-BO</Identifier><Identifier type="Trial Acronym">PROPHET</Identifier></Identifiers><Indications><Indication id="158">HIV infection</Indication></Indications><BiomarkerNames><BiomarkerName id="419" role="Therapeutic effect marker" type="Anthropomorphic">Waist to Hip Ratio</BiomarkerName><BiomarkerName id="1857" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD4</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="44218" role="Disease marker;Therapeutic effect marker" type="Genomic">Human immunodeficiency virus RNA</BiomarkerName><BiomarkerName id="46506" role="Therapeutic effect marker" type="Cellular">T-Lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>abacavir</Name><Drug id="6242">abacavir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>atazanavir</Name><Drug id="15254">atazanavir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>cobicistat</Name><Drug id="62275">cobicistat</Drug></Intervention><Intervention type="InterventionPrimary"><Name>darunavir</Name><Drug id="32981">darunavir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>dolutegravir</Name><Drug id="59062">dolutegravir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>efavirenz</Name><Drug id="10172">efavirenz</Drug></Intervention><Intervention type="InterventionPrimary"><Name>elvitegravir</Name><Drug id="51371">elvitegravir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>emtricitabine</Name><Drug id="4728">emtricitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>fosamprenavir</Name><Drug id="24471">fosamprenavir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>lamivudine</Name><Drug id="3474">lamivudine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>lopinavir + ritonavir</Name><Drug id="14681">lopinavir + ritonavir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>nevirapine</Name><Drug id="3700">nevirapine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>raltegravir</Name><Drug id="54488">raltegravir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>rilpivirine hydrochloride</Name><Drug id="52857">rilpivirine hydrochloride</Drug></Intervention><Intervention type="InterventionPrimary"><Name>ritonavir</Name><Drug id="7310">ritonavir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>tenofovir disoproxil fumarate</Name><Drug id="14493">tenofovir disoproxil fumarate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10172">efavirenz</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="14493">tenofovir disoproxil fumarate</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="14681">lopinavir + ritonavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15254">atazanavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="24471">fosamprenavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="32981">darunavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3474">lamivudine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3700">nevirapine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4728">emtricitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="51371">elvitegravir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="52857">rilpivirine hydrochloride</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54488">raltegravir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59062">dolutegravir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="62275">cobicistat</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6242">abacavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7310">ritonavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1043681">Univeristat Duisburg-Essen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17392">Janssen-Cilag Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3700" type="Drug"><TargetEntity id="170581" type="siDrug">Nevirapine</TargetEntity></SourceEntity><SourceEntity id="6242" type="Drug"><TargetEntity id="173602" type="siDrug">Abacavir sulfate</TargetEntity><TargetEntity id="213610" type="siDrug">Abacavir succinate</TargetEntity></SourceEntity><SourceEntity id="3474" type="Drug"><TargetEntity id="184356" type="siDrug">Lamivudine</TargetEntity></SourceEntity><SourceEntity id="4728" type="Drug"><TargetEntity id="190016" type="siDrug">Emtricitabine</TargetEntity></SourceEntity><SourceEntity id="10172" type="Drug"><TargetEntity id="207217" type="siDrug">Efavirenz</TargetEntity></SourceEntity><SourceEntity id="7310" type="Drug"><TargetEntity id="207282" type="siDrug">Ritonavir</TargetEntity></SourceEntity><SourceEntity id="14493" type="Drug"><TargetEntity id="246665" type="siDrug">Tenofovir disoproxil fumarate</TargetEntity></SourceEntity><SourceEntity id="15254" type="Drug"><TargetEntity id="257722" type="siDrug">Atazanavir sulfate</TargetEntity></SourceEntity><SourceEntity id="24471" type="Drug"><TargetEntity id="278740" type="siDrug">Fosamprenavir sodium</TargetEntity><TargetEntity id="285394" type="siDrug">Fosamprenavir calcium</TargetEntity></SourceEntity><SourceEntity id="14681" type="Drug"><TargetEntity id="291602" type="siDrug">Lopinavir/ritonavir</TargetEntity></SourceEntity><SourceEntity id="32981" type="Drug"><TargetEntity id="310828" type="siDrug">Darunavir</TargetEntity></SourceEntity><SourceEntity id="52857" type="Drug"><TargetEntity id="336587" type="siDrug">Rilpivirine hydrochloride</TargetEntity><TargetEntity id="422002" type="siDrug">Rilpivirine</TargetEntity></SourceEntity><SourceEntity id="51371" type="Drug"><TargetEntity id="414415" type="siDrug">Elvitegravir</TargetEntity></SourceEntity><SourceEntity id="54488" type="Drug"><TargetEntity id="428015" type="siDrug">Raltegravir potassium</TargetEntity></SourceEntity><SourceEntity id="59062" type="Drug"><TargetEntity id="466915" type="siDrug">Dolutegravir sodium</TargetEntity></SourceEntity><SourceEntity id="62275" type="Drug"><TargetEntity id="644627" type="siDrug">Cobicistat</TargetEntity></SourceEntity><SourceEntity id="1043681" type="Company"><TargetEntity id="5035544598" type="organizationId">Univeristat Duisburg Essen</TargetEntity></SourceEntity><SourceEntity id="1120539" type="Company"><TargetEntity id="5050649655" type="organizationId">Deutsche Arbeitsgemeinschaft niedergelassener Aerzte in der Versorgung HIV Infizierter eV</TargetEntity></SourceEntity><SourceEntity id="17392" type="Company"><TargetEntity id="4296968679" type="organizationId">Janssen-Cilag Ltd</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="138" type="Action"><TargetEntity id="416" type="Mechanism">DNA-Directed DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="1065" type="Mechanism">DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="3618" type="Mechanism">Nucleic Acid Polymerase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1671" type="Action"><TargetEntity id="435" type="Mechanism">HIV Integrase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="204" type="Action"><TargetEntity id="436" type="Mechanism">HIV Protease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7424" type="Action"><TargetEntity id="2211" type="Mechanism">Cytochrome P450 CYP3A4 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="768" type="Action"><TargetEntity id="4056" type="Mechanism">HIV-1 Protease Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1120539">Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1043681">Univeristat Duisburg-Essen</Company><Company id="17392">Janssen-Cilag Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1016">HIV-1 reverse transcriptase inhibitor</Action><Action id="12395">HIV GAG protein inhibitor</Action><Action id="138">DNA polymerase inhibitor</Action><Action id="1671">HIV integrase inhibitor</Action><Action id="1832">Nucleoside reverse transcriptase inhibitor</Action><Action id="1833">Non-nucleoside reverse transcriptase inhibitor</Action><Action id="204">HIV protease inhibitor</Action><Action id="551">RNA DNA polymerase inhibitor</Action><Action id="71851">HIV GAG POL polyprotein inhibitor</Action><Action id="7418">Cytochrome P450 3 inhibitor</Action><Action id="7424">Cytochrome P450 3A4 inhibitor</Action><Action id="7588">HIV-1 integrase inhibitor</Action><Action id="768">HIV-1 protease inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="32411">Hepatitis B virus replication inhibitor</Class><Class id="7293">Synergist</Class><Class id="747">HIV replication inhibitor</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="805">Daily dosing</Technology><Technology id="723">Drug coating</Technology><Technology id="175">Drug combination</Technology><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="743">Granule</Technology><Technology id="1646">Injectable controlled release formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="701">Nucleoside synthesis</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="742">Pellet</Technology><Technology id="667">Peptidomimetic</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="630">Stereochemistry</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="745">Suspension</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><PatientCountEnrollment>480</PatientCountEnrollment><DateStart>2014-08-01T00:00:00Z</DateStart><DateEnd type="actual">2017-11-14T00:00:00Z</DateEnd><DateChangeLast>2018-07-24T07:52:22Z</DateChangeLast><DateAdded>2016-03-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>ICH Study Center</Affiliation><Email>mail@ich-studycenter.com</Email><Name>Christian Hoffmann</Name><Phone>040 284073-70</Phone></Contact><Contact type="Scientific contact"><Affiliation>ICH Study Center</Affiliation><Email>mail@ich-studycenter.com</Email><Name>Christian Hoffmann</Name><Phone>+49(0)40 284073-70</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The patient's age at the date of inclusion is&amp;gt; 18 years&lt;/li&gt;&lt;li&gt;Chronic HIV-infection, to date without HIV-treatment and indication of therapy start&lt;/li&gt;&lt;li&gt;Signed patient informed consent&lt;/li&gt;&lt;li&gt;Planned treatment initiation with backbone consiting of TDF + FTC or ABC + 3TC in combination with a third antiretroviral drug&lt;/li&gt;&lt;li&gt;The third substance is either a non-nucleosidale-reverse-transcriptase-inhibitor NNRTI: (efavirenz, nevirapin, rilpivirin), a boosted protease-inhibitor (PI/r: darunavir/r, lopinavir/r, atazanavir/r, fosamprenavir/r) or  integrase-inhibitor (INI: raltegravir, elvitegravir/c, dolutegravir)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Initiation of antiretroviral therapy which is not based on a backbone of TDF + FTC or ABC/3TC in combination with a NNRTI, PI/r or INI&lt;/li&gt;&lt;li&gt;Acute HIV-infection, seroconversion&lt;/li&gt;&lt;li&gt;Prior use of antiretroviral drugs (a short-term therapy within the scope of a 'mother-to-child-transmission-prophylaxis'  is allowed)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Percent of patients with HIV-1 RNA &lt; 200 cp/ml (ITT analysis)</Description><Timeframe>At month 24</Timeframe></Measure><Measure><Description>Percent of patients with virological failure. Failure will be defined as confirmed VL &gt; 200 cp/ml (based on the DHHS definition of virological failure) or a viral rebound to &gt; 200 cp/ml combined with subsequent treatment modification</Description></Measure><Measure><Description>CD4 cell change and absolute CD4 cell count (involving ITT and AT analysis), particularly in late presenters (defined as per the European consensus CD4 &lt; 350/microl and/or history of an AIDS-defining event) in comparison to patients with CD4 &gt;/= 350/microl and early/less advanced HIV-disease</Description><Timeframe>At baseline, months 12 and 24</Timeframe></Measure><Measure><Description>Percent of late presenters with immune reconstitution to &gt; 750 CD4/microl compared to patients with CD4 &gt;/= 350/microl and no history of AIDS-defining event</Description></Measure><Measure><Description>Costs and cost effectiveness of current first-line HIV-treatment strategies and HIV-care considering the covariables and methods of the DAGNAE K3A study</Description></Measure><Measure><Description>Annotations: Efficacy analysis will be stratified according to: the use of the third antiretroviral agent (PI/r versus NNRTI versus INI), NRTI Backbone, Baseline HIV-RNA categories (ie, &gt; 100.000 cp/ml versus &lt;/= 100000 cp/ml) and  baseline CD4 categories (ie, &lt; 200, 200 to 349, 350 to 499, &gt;/= 500/microl). For certain questions patients are splitted in late presenters (defined as per the European consensus CD4 &lt; 350/microl and/or history of an AIDS-defining event) in comparison to patients with CD4 &gt;/= 350/microl and early/less advanced HIV-disease</Description><Timeframe>Baseline</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Percent with HIV-1 RNA &lt; 200 cp/ml (ITT analysis) (As-treated [AT] analysis)</Description><Timeframe>At 12 and 24 months</Timeframe></Measure><Measure><Description>Percent &lt; 50 cp/ml  (involving ITT analysis [based on the above mentioned snapshot algorithm]  and AT analysis)</Description><Timeframe>At 12 and 24 months</Timeframe></Measure><Measure><Description>Durability of first-line ART, treatment discontinuations and modifications</Description></Measure><Measure><Description>Clinical outcomes and cost of late presenters (defined as per the European consensus CD4 &lt; 350 and/or history of an AIDS-defining event) in comparison to patients with early/less advanced HIV-disease</Description></Measure><Measure><Description>Weight, blood pressure, waist/hip-measurement, quality of life, depression and phyisical well-being</Description><Timeframe>At baseline, months 12 and 24</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This 'PROPHET' study deliberately gave no recommendations on regimen use. Important factors being investigated in this study included therapy outcomes, physical and mental well-being, as well as quality of life and health care costs. Objective of this study was to obtain insight into HIV treatment strategies in Germany, in order to identify ways to improve medical care of the HIV-infected population.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Total of 480 HIV-infected subjects beginning initial anitretroviral therapy would be followed for two years. Clinical and health economic data would be documented and analyzed. This study consist of three arms:&lt;br/&gt;Arm 1: subjects would receive &lt;ulink linkType="Drug" linkID="14493"&gt;tenofovir&lt;/ulink&gt; (TDF) + &lt;ulink linkType="Drug" linkID="4728"&gt;emtricitabine&lt;/ulink&gt; (FTC)  or &lt;ulink linkType="Drug" linkID="6242"&gt;abacavir&lt;/ulink&gt; (ABC) + &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt; (3TC) plus one not nucleosidale reverse transcriptase inhibitor (NNRTI) (&lt;ulink linkType="Drug" linkID="10172"&gt;efavirenz&lt;/ulink&gt; [EFV] or &lt;ulink linkType="Drug" linkID="3700"&gt;nevirapine&lt;/ulink&gt; [NVP] or &lt;ulink linkType="Drug" linkID="52857"&gt;rilpivirin&lt;/ulink&gt; [RPV]).&lt;br/&gt;Arm 2: subjects would receive tenofovir (TDF) + emtricitabin (FTC) or abacavir (ABC) + lamivudin (3TC) plus one boosted protease inhibitor (PI/r) (&lt;ulink linkType="Drug" linkID="32981"&gt;darunavir&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt; [DRV/r] or &lt;ulink linkType="Drug" linkID="14681"&gt;lopinavir/ritonavir&lt;/ulink&gt; [LPV/r] or   &lt;ulink linkType="Drug" linkID="15254"&gt;atazanavir&lt;/ulink&gt;/ritonavir [ATV/r] or &lt;ulink linkType="Drug" linkID="24471"&gt;fosamprenavir&lt;/ulink&gt;/ritonavir  [FPV/r]).&lt;br/&gt;Arm 3: subjects would receive tenofovir (TDF) + emtricitabin (FTC) or abacavir (ABC) + lamivudin (3TC)  plus one integrase inhibitor (INI) (&lt;ulink linkType="Drug" linkID="54488"&gt;raltegravir&lt;/ulink&gt; [RAL] or &lt;ulink linkType="Drug" linkID="51371"&gt;elvitegravir&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="62275"&gt;cobicistat&lt;/ulink&gt; [EVG/c] or &lt;ulink linkType="Drug" linkID="59062"&gt;dolutegravir&lt;/ulink&gt; [DTG]).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>ZIBP Dienstleistung GmbH, Medizinisches Infektiologiezentrum Berlin</Name><Contacts></Contacts></Site><Site><Name>ifi- Institut für Interdisziplinäre Medizin, ICH Study Center Hamburg</Name><Contacts></Contacts></Site><Site><Name>Medizinisches Versorgungszentrum der Medizinischen Hochschule Hannover, Zentrum Innere Medizin Klinik für Immunologie und Rheumatologie,  Hannover</Name><Contacts></Contacts></Site><Site><Name>Forschung GbR MVZ Dr. Mauss/Schmutz/Dr. Athmann/Dr. Hegener,  Düsseldorf</Name><Contacts></Contacts></Site><Site><Name>Universitätsklinikum Essen, Klinik für Dermatologie und Venerologie,  Essen</Name><Contacts></Contacts></Site><Site><Name>Köln</Name><Contacts></Contacts></Site><Site><Name>Klinik I für Innere Medizin,  Köln</Name><Contacts></Contacts></Site><Site><Name>Universitätsklinikum Bonn, Medizinische Klinik I Klinisches Studienzentrum Immunologie,  Bonn</Name><Contacts></Contacts></Site><Site><Name>Infektio Research Friedenstraße,  Frankfurt a.M.</Name><Contacts></Contacts></Site><Site><Name>Infektio Research Stresemannallee,  Frankfurt a.M.</Name><Contacts></Contacts></Site><Site><Name>Stuttgart</Name><Contacts></Contacts></Site><Site><Name>MVZ Karlsplatz,  München</Name><Contacts></Contacts></Site><Site><Name>Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Sektion Klinische Infektiologie,  München</Name><Contacts></Contacts></Site><Site><Name>München</Name><Contacts></Contacts></Site><Site><Name>IZAR, Klinikum rechts der Isar, Technische Universität München,,  München</Name><Contacts></Contacts></Site><Site><Name>Infektio Research Freiburg,  Freiburg</Name><Contacts></Contacts></Site><Site><Name>Zentrum f. Med. Studien UG,  Hannover</Name><Contacts></Contacts></Site><Site><Name>Halle/Saale</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7107">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1019">German Clinical Trials Register (DRKS)</Name><Identifiers><Identifier type="Secondary Organisational">DRKS00006321</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="HIV infection" id="9195"><Endpoint>Assessment of virological response</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9197">Assessment of virological failure</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9212"><Endpoint>Assessment of Viral Load</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9213">Assessment of HIV RNA levels</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9214"><Endpoint>Assessment of CD4 Cell Responses</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9215">Assessment of CD4 cell count/percentage</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9218"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9280"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9284">Assessment of clinical efficacy/response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="29585"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="29586">Assessment of cost effectiveness</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="HIV infection" id="9212"><Endpoint>Assessment of Viral Load</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9213">Assessment of HIV RNA levels</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9214"><Endpoint>Assessment of CD4 Cell Responses</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9215">Assessment of CD4 cell count/percentage</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9257"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9260"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9280"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9294">Assessment of changes in antiretroviral treatment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="29585"><Endpoint>Health Economic Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="31479"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="44853"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9255">Assessment of treatment discontinuation</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5339"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="HIV infection" id="34441"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5364">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6874"><Criterion>Subjects on Prior/Concurrent Antiretroviral Drugs</Criterion></Exclusion><Exclusion disease="HIV infection" id="6878"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2016-09-13T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>25.42 Months</EnrollmentPeriod><EnrollmentRate>18.88 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-03-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-09-27T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-02-28T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="256719"><TitleDisplay>A study examining the effect of etanercept (Enbrel) on inflammation in the brain</TitleDisplay><TitleOfficial>A double-blind, placebo-controlled study of the effect of a TNF alpha inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with Mild Cognitive Impairment due to AD-Intermediate likelihood</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2015-002145-63</Identifier><Identifier type="ISRCTN">ISRCTN12472821</Identifier><Identifier type="Secondary Organisational">INMiND-02</Identifier></Identifiers><Indications><Indication id="14">Alzheimers disease</Indication><Indication id="3122">Mild cognitive impairment</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="174" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-12</BiomarkerName><BiomarkerName id="175" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-10</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="249" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-13</BiomarkerName><BiomarkerName id="252" role="Therapeutic effect marker" type="Genomic;Proteomic">Interferon gamma</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="316" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-4</BiomarkerName><BiomarkerName id="11622" role="Therapeutic effect marker" type="Genomic">Interleukin 1</BiomarkerName><BiomarkerName id="12205" role="Therapeutic effect marker" type="Cellular;Structural (imaging)">Microglia</BiomarkerName><BiomarkerName id="32605" role="Therapeutic effect marker" type="Genomic;Proteomic">Transforming Growth Factor beta</BiomarkerName><BiomarkerName id="36226" role="Therapeutic effect marker" type="Proteomic">Amyloid</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>etanercept</Name><Drug id="4567">etanercept</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4567">etanercept</Drug><IndicationsPioneer><Indication id="3122">Mild cognitive impairment</Indication></IndicationsPioneer><Companies><Company><Company id="1042052">Alzheimer's Drug Discovery Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1045801">The European Union</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1084178">Alzheimers Society</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20678">University Of Southampton</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4567" type="Drug"><TargetEntity id="213242" type="siDrug">Etanercept</TargetEntity></SourceEntity><SourceEntity id="1042052" type="Company"><TargetEntity id="5035525921" type="organizationId">Alzheimer's Drug Discovery Foundation</TargetEntity></SourceEntity><SourceEntity id="1045801" type="Company"><TargetEntity id="8589934582" type="organizationId">European Union</TargetEntity></SourceEntity><SourceEntity id="1084178" type="Company"><TargetEntity id="4298156100" type="organizationId">Alzheimer's Society</TargetEntity></SourceEntity><SourceEntity id="20678" type="Company"><TargetEntity id="4296787590" type="organizationId">University of Southampton</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3122" type="ciIndication"><TargetEntity id="G31.84" type="ICD10"></TargetEntity><TargetEntity id="D060825" type="MeSH"></TargetEntity><TargetEntity id="-813198932" type="omicsDisease"></TargetEntity><TargetEntity id="108" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20678">University Of Southampton</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1042052">Alzheimer's Drug Discovery Foundation</Company><Company id="1045801">The European Union</Company><Company id="1084178">Alzheimers Society</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="511">TNF antagonist</Action><Action id="721">TNF binding agent</Action><Action id="8222">Type II TNF receptor modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="1545">Anticancer</Class><Class id="2953">Anti-inflammatory</Class><Class id="396">Immunosuppressant</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="127">Cell culture</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="894">Liquid formulation</Technology><Technology id="84">Protein fusion</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>46</PatientCountEnrollment><DateStart>2015-10-15T00:00:00Z</DateStart><DateEnd type="actual">2018-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-11-23T08:40:23Z</DateChangeLast><DateAdded>2016-03-28T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Memory Assessment &amp; Research Centre</Affiliation><Email>c.holmes@soton.ac.uk</Email><Name>Dr Clive Holmes</Name><Phone>+44 (0)23 80 475206</Phone></Contact><Contact type="Public contact"><Affiliation>University of Southampton</Affiliation><Email>ch4@soton.ac.uk</Email><Name>Prof Holmes</Name><Phone>02380475206</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All subjects must have the capacity to make an informed decision as to whether they would like to take part in this specific clinical research trial&lt;/li&gt;&lt;li&gt;A subject can be male or female and they must be between 50 to 90 years old&lt;/li&gt;&lt;li&gt;A subject must have received a minimum of seven years of formal education&lt;/li&gt;&lt;li&gt;A subject must be able to hear, read, write and perform study neuro-psychological tests in English&lt;/li&gt;&lt;li&gt;A subject must have adequate visual and auditory acuity to allow neuro-psychological testing, based on the research clinician's judgement&lt;/li&gt;&lt;li&gt;A subject must fulfil the NIA-AA criteria for the diagnosis of mild cognitive impairment due to AD at the screening visit (Albert et al, 2011). A subject must have a MOCA score of 19 to 25 inclusive at screening, at the discretion of the principal investigator&lt;/li&gt;&lt;li&gt;A subject must have a study partner who spends at least 8 h a month with the subject. The study partner may be a close friend or a neighbour and not necessarily a close relative, spouse, son or daughter, and should be present at all visits. Every effort should be made to ensure that the study partner will be the same throughout the study. If it becomes necessary for the study partner to change, the new study partner must satisfy the requirements of this criterion and the change of study partner must be clearly documented&lt;/li&gt;&lt;li&gt;A subject must have been on a stable medication regime for &gt; 3 months prior to screening&lt;/li&gt;&lt;li&gt;Women of child bearing potential must use adequate contraception to prevent pregnancy during the study and must continue to us contraception for at least 4 weeks after the last study dose&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;General criteria:&lt;ul&gt;&lt;li&gt;Inability or refusal to provide informed consent from subject or study partner&lt;/li&gt;&lt;li&gt;Absence of study partner&lt;/li&gt;&lt;li&gt;Unlikely to cooperate in the study, not able to attend scheduled examinations and visits, or not able to follow study instructions, left to the research clinician's judgement&lt;/li&gt;&lt;li&gt;Participation in another study with administration of any investigational drug in the previous 3 months or already enrolled in another study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Medical and therapeutic criteria:&lt;ul&gt;&lt;li&gt;Parkinson's disease, dementia with Lewy Bodies or clinically significant Parkinsonian symptoms&lt;/li&gt;&lt;li&gt;Vascular disorder (Modified Hachinski Ischemic Scale score&amp;gt; 4)&lt;/li&gt;&lt;li&gt;Recent transient ischemic attack (TIA) - within the last 3 months&lt;/li&gt;&lt;li&gt;Signs of major cerebrovascular disease on MRI or CT scan prior to entry into study, (ie, evidence of an established cortical or basal ganglia infarct)&lt;/li&gt;&lt;li&gt;Signs of major cerebrovascular disease on the MRI performed at the screening imaging visit prior to the amyloid and microglial PET scans&lt;/li&gt;&lt;li&gt;Any other previous or ongoing chronic or recurrent disease of the central nervous system, including demyelinating disease or psychiatric diseases, that may have an impact on cognitive performance, left to the research clinician's judgement&lt;/li&gt;&lt;li&gt;Any of the following laboratory abnormalities at the screening visit:&lt;ul&gt;&lt;li&gt;Clinically significant vitamin B12 levels less than the lower limit of normal&lt;/li&gt;&lt;li&gt;Clinically significant folate levels less than the lower limit of normal&lt;/li&gt;&lt;li&gt;Clinically significant thyroid-stimulating hormone (TSH) levels greater than the upper limit of normal and a clinically significant free thyroxine (FT4) level lower than the lower limit of normal (subjects who are successfully treated for folate and vitamin B12 deficiencies or hypothyroidism may be re-screened after 3 months)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subjects with a previous or present history of severe medical conditions, or medical conditions which are poorly controlled, such as hypertension or diabetes, left to the research clinician's judgement&lt;/li&gt;&lt;li&gt;History of alcohol or drug dependence or abuse within the last two years. Current alcohol&amp;gt; 35 units per week for men, or &amp;gt; 28 units per week for women, or drug abuse, at the discretion of the research clinician&lt;/li&gt;&lt;li&gt;Surgical intervention planned during the study period&lt;/li&gt;&lt;li&gt;Treatment with immunosuppressive drugs including any systemic corticosteroid drugs (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted)&lt;/li&gt;&lt;li&gt;Treatment with benzodiazepines within a period of 3 days prior to (11C) (R)-PK-111-95 PET scans imaging&lt;/li&gt;&lt;li&gt;Vaccination or immunization with any live vaccine (eg,: polio, rubella, yellow fever) within the past 30 days&lt;/li&gt;&lt;li&gt;Pregnancy or breast feeding&lt;/li&gt;&lt;li&gt;Severe hepatic, renal or cardiac disease&lt;/li&gt;&lt;li&gt;Previous use of a TNF-alpha agent&lt;/li&gt;&lt;li&gt;Known skin photosensitivity&lt;/li&gt;&lt;li&gt;Infection in past 4 weeks or active infection&lt;/li&gt;&lt;li&gt;Heart failure: New York Heart Association (NYHA) grade 3 to 4&lt;/li&gt;&lt;li&gt;History of blood disorders or current WCC&amp;lt;/= 3.5 x 10(9)/l; platelet count &amp;lt;/= 100 x 10(9)/l; Hb &amp;lt;/= 10 g/dl&lt;/li&gt;&lt;li&gt;Active or latent tuberculosis&lt;/li&gt;&lt;li&gt;Rheumatoid arthritis; psoriasis; psoriatic arthritis or ankylosing spondylitis&lt;/li&gt;&lt;li&gt;Septic arthritis in past 12 months&lt;/li&gt;&lt;li&gt;Sepsis of prosthesis in past 12 months&lt;/li&gt;&lt;li&gt;Chronic leg ulcers&lt;/li&gt;&lt;li&gt;Indwelling urinary catheter&lt;/li&gt;&lt;li&gt;Pulmonary fibrosis&lt;/li&gt;&lt;li&gt;History of neoplasms/malignancies in past five years&lt;/li&gt;&lt;li&gt;Pre-malignant conditions including Barrett's oesophagus; cervical dysplasia; large bowel polyps&lt;/li&gt;&lt;li&gt;Other clinically significant abnormality on physical, neurological, ECG or laboratory examination that could compromise the study evaluations or be detrimental to the patient during the course of the study&lt;/li&gt;&lt;li&gt;Use of experimental medications for AD, or any other investigational medication or device, within 60 days. Patients who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Imaging exclusion criteria:&lt;ul&gt;&lt;li&gt;Subjects with significant cortical or basal ganglia infarct or other significant pathology found on MRI brain scan&lt;/li&gt;&lt;li&gt;Subject with a negative amyloid PET scan. NB: subjects with a positive amyloid PET scan or a border-line positive PET scan will be included in the study. The final decision on whether the amyloid PET scan is negative, border-line positive, or positive, will rest with the principle investigators at the Wolfson Molecular Imaging Center&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The primary objective is to ascertain the change in microglial activation on PK-111 95 PET scans from base-line to the final imaging visit in the treatment group compared to the placebo group. The study is powered on the basis that a positive result would be a 50% reduction in microglial activation in subjects receiving the IP, versus the reduction in microglial activation in the placebo group</Description><Timeframe>The first PK-111 95 PET scan to evaluate microglial activation in a subject will be done during the screening period of the study. The comparator scan will be done at a final imaging visit wihich will take place at week 51 of the 52 week treatment period</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To ascertain the change in the primary cognitive outcome measure, the Montreal Cognitive Assessment, (MOCA), from baseline to final treatment visit in the treatment group compared to the placebo group</Description><Timeframe>MOCA: evaluated at baseline (week 0), weeks 13, 26, 39 and at the end of treatment period, week 52</Timeframe></Measure><Measure><Description>To ascertain the change in cortical amyloid load on AMYVID PET scans from baseline to the final imaging visit in the treatment group compared to the placebo group</Description><Timeframe>AMYVID PET scan: the baseline scan will be done duing the screening period (8 to 0 weeks), and 1 week before the end of the 52 week treatment period</Timeframe></Measure><Measure><Description>Exploratory objectives: ascertain the change in the first of the exploratory cognitive outcome measures, the Repeatable Battery for the Assessment of Neuro-psychological Status, (RBANS)</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: ascertain the change in the second of the exploratory cognitive outcome measures, the Free and Cued Recall Selective Reminding Test with Immediate Recall (FCSRT-IR)</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: ascertain the change in the Cornell Scale score</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: ascertain the change in the behavioral assessment the Apathy Inventory</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: ascertain the change in the behavioral assessment the Apathy Clinicians Diagnostic Criteria</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: ascertain the change in the levels of plasma markers of neuro-inflammation (pro and anti-inflammatory cytokines: IL-1; IL-6, TNF-alpha, IFN-gamma, IL-4, IL-10, IL-12, IL-13; CRP, and TGF-beta)</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives:  study the relationship between the changes in the levels of plasma markers of neuro-inflammation (IL-1; IL-6, TNF-alpha, IFN-gamma, IL-4, IL-10, IL-12, IL-13; CRP, TGF-beta) and changes of microglial activation on PK1195 PET scan, and clinical outcomes</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: study the relationship between the changes in the levels of plasma markers of neuro-inflammation (IL-1; IL-6, TNF-alpha, IFN-gamma, IL-4, IL-10, IL-12, IL-13; CRP, TGF-β) and changes of microglial activation on [11C] (R)-PK-111-95 PET scan, the change in cortical amyloid load on AMYVID PET scans and clinical outcomes</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: examine the penetration of etanercept across the blood brain barrier in patients with mild cognitive impairment due to AD</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure><Measure><Description>Exploratory objectives: optional lumbar puncture to examine the effects of etanercept on inflammatory markers in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment due to AD, and the relationship with clinical outcomes. CSF will be collected from 4 to 10 patients at visit 4, +/- 2 weeks. Tests will be done on the cerebro-spinal fluid samples to measure levels of etanercept, to determine cytokine levels (cytokine assays using MESOSCALE ELISA), and possibly to determine levels of amyloid protein</Description><Timeframe>The neuro-psychological testing related outcome measures will be done at baseline, visit 1, and repeated at visit 3 (13 weeks into treatment period), visit 4, (26 weeks), visit 5 (39 weeks), visit 6, (52 weeks on treatment, end of treatment period). Procedures carried out: PET scans x 4; MRI scans x 2; CXR x 1; blood tests x 10; urine tests x 8; ECG x 1, and as required; optional LP x 1; study injection, sub-cutaneous, x 53; physical examination x 8; neuro-psychological testing x 6</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study  hypothesized that in mild cognitive impairment (MCI)-due to Alzheimer's disease (AD), systemic Alzheimer's and elevated systemic levels of TNF-alpha cause partially activated, or primed, microglial cells, to become fully activated, which can be modulated by the administration of a peripheral TNF-alpha inhibitor, etanercept (&lt;ulink linkType="Drug" linkID="4567"&gt;Enbrel&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;This study would answer the following questions:&lt;br/&gt;Would the administration of a peripheral TNFalpha inhibitor, etanercept, over a 12 months treatment period, reduce microglial activation in patients with MCI due to AD-intermediate likelihood, and reduce cognitive and behavioural decline?&lt;br/&gt;The level of microglial activation would be directly measured with a specialist brain scan, which was called a (11C) (R)-PK-111-95 PET scan, at base-line and at the end of the 12 month treatment period.&lt;/para&gt;&lt;para&gt;Secondary objectives of the trial:&lt;br/&gt;To ascertain the change in the primary cognitive outcome measure, the Montreal Cognitive Assessment, (MOCA), from baseline to final treatment visit in the treatment group compared to the placebo group (the MOCA was a well validated and widely used assessment tool which measures 8 cognitive domains within a series of 13 tests: visuospatial/executive function, memory, language, abstraction, delayed recall and orientation. The highest possible score was 30. A score &amp;gt; 26 represents normal cognitive function).&lt;br/&gt;To ascertain the change in cortical amyloid load on Amyvid PET scans from base-line to the final imaging visit in the treatment group compared to the placebo group.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either etanercept (50 mg sc qw) or placebo, for 52 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Prof Holmes</Name></Contact></Contacts></Site><Site><Name>Memory Assessment &amp; Research Centre</Name><Contacts></Contacts></Site><Site><Name>Memory Clinic</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Alzheimers disease</Disease><PatientSegments><PatientSegment><PatientSegment id="152">Subjects with Mild Cognitive Impairment(MCI)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2015-002145-63</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN12472821</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Alzheimers disease" id="2220"><Endpoint>Positron Emission Tomography (PET) Findings</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Alzheimers disease" id="44013"><Endpoint>Neurological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Alzheimers disease" id="2207"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2220"><Endpoint>Positron Emission Tomography (PET) Findings</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2227"><Endpoint>Assessment of Cerebrospinal Fluid (CSF)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2289"><Endpoint>Cognitive, Global and Functional Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2323"><Endpoint>Assessment of Caregiver Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2395"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2850"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Alzheimers disease" id="6697">Assessment of C reactive protein (CRP)</SubEndpoint><SubEndpoint disease="Alzheimers disease" id="6698">Interleukin (IL)</SubEndpoint><SubEndpoint disease="Alzheimers disease" id="6699">Assessment of tumor necrosis factor alpha (TNFa)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="10720"><Endpoint>Assessment of Cardiac Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="10722"><Endpoint>Assessment of Renal Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="10723"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Alzheimers disease" id="2243">Assessment of hematological parameters</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="10726"><Endpoint>Assessment of Physical Examination</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="34323"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="44013"><Endpoint>Neurological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="45687"><Endpoint>Assessment of Neuropsychological Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Alzheimers disease" id="967"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="971">Subjects with history of stable doses of Alzheimer's disease therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Alzheimers disease" id="1006"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1011">Subjects with availability of a reliable partner/caregiver</SubCriterion><SubCriterion disease="Alzheimers disease" id="1017">Fluency in local language/english</SubCriterion><SubCriterion disease="Alzheimers disease" id="1037">Subjects able to communicate in the language specified in the protocol</SubCriterion><SubCriterion disease="Alzheimers disease" id="6683">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Alzheimers disease" id="6674"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="33405">Subjects with a protocol specified value in Montreal Cognitive Assessment (MoCA)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Alzheimers disease" id="34131"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1036">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Alzheimers disease" id="34348"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1020">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Alzheimers disease" id="34932"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1021">Subjects likely to be compliant to the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Alzheimers disease" id="35008"><Criterion>Subjects with Cognitive Impairment</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="947">Subjects with Mild Cognitive Impairment (MCI)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Alzheimers disease" id="1423"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1419">Multi-infarct/vascular dementia (Modified Hachinski/Hachinski ischemic score (HIS) &gt; 7)</SubCriterion><SubCriterion disease="Alzheimers disease" id="1420">Mixed dementia (Modified Hachinski/Hachinski ischemic score (HIS) 4 to 7)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1433"><Criterion>Abnormal MRI Findings, Other Than Suggestive of Alzheimer's Disease</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1441"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1449">Subjects co-morbid with Parkinson's disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1457"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1573">Subjects co-morbid with substance abuse disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1475"><Criterion>Subjects co-morbid with hypertension</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1483"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1490">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Alzheimers disease" id="1494">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Alzheimers disease" id="1951">Subjects with dermatological diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1484"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1485"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1493"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1516"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1525">Subjects with history of/schedule for corticosteroids for other indication</SubCriterion><SubCriterion disease="Alzheimers disease" id="1531">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1538"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1557">Subjects with History of surgery/transplant</SubCriterion><SubCriterion disease="Alzheimers disease" id="1561">Subjects with history of participation in clinical trials</SubCriterion><SubCriterion disease="Alzheimers disease" id="8270">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1948"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="25425"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1551">Subjects unable to give informed consent/assent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="25862"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1479">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="26731"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1556">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="27026"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1442">Subjects co-morbid with stroke/transient ischemic attack</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="27112"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1486">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2016-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>10.55 Months</EnrollmentPeriod><EnrollmentRate>4.36 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-03-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-05-28T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="307014"><TitleDisplay>Pentoxifyllin ointment in treatment of bedsore</TitleDisplay><TitleOfficial>Comparing efficacy of pentoxifyllin ointment and placebo in treatment of bedsore in patients hospitalized in intensive care unit</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201402233449N16</Identifier><Identifier type="Secondary Organisational">92-03-33-24364</Identifier></Identifiers><Indications><Indication id="2568">Decubitus ulcer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pentoxifylline</Name><Drug id="44306">pentoxifylline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44306">pentoxifylline</Drug><IndicationsPioneer><Indication id="2568">Decubitus ulcer</Indication></IndicationsPioneer><Companies><Company><Company id="1043016">Tehran University of Medical Sciences</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44306" type="Drug"><TargetEntity id="143975" type="siDrug">Pentoxifylline</TargetEntity></SourceEntity><SourceEntity id="1043016" type="Company"><TargetEntity id="5035525669" type="organizationId">Tehran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="2568" type="ciIndication"><TargetEntity id="L89" type="ICD10"></TargetEntity><TargetEntity id="10011985" type="MEDDRA"></TargetEntity><TargetEntity id="D003668" type="MeSH"></TargetEntity><TargetEntity id="-660771389" type="omicsDisease"></TargetEntity><TargetEntity id="496" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="8052" type="Action"><TargetEntity id="466" type="Mechanism">Phosphodiesterase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043016">Tehran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="8052">Phosphoric diester hydrolase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class></Class><Technologies><Technology id="641">Controlled release formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2014-02-01T00:00:00Z</DateStart><DateChangeLast>2017-08-09T05:42:09Z</DateChangeLast><DateAdded>2017-08-07T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Tehran University of Medical Sciences</Affiliation><Email>khalilih@tums.ac.ir</Email><Name>Hossein Khalili</Name><Phone>00982166954715 00</Phone></Contact><Contact type="Public contact"><Affiliation>Tehran University of Medical Sciences</Affiliation><Email>khalilih@tums.ac.ir</Email><Name>Hossein Khalili</Name><Phone>00982166954715 00989122979329</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Critically ill patients with grade 1 or 2 of bedsore&lt;/li&gt;&lt;li&gt;Who will be hospitalized in Intensive Care Unit (ICU) for at-least 14 days and without history of pentoxifyllin hypersensitivity&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with severe bedsore requiring antibiotic therapy and worsening of bedsore during treatment course will be excluded from the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Grade of bedsore: 2-digit Stirling scale</Description><Timeframe>At ICU admission and then day 14 of hospitalization</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of this study is to compare the efficacy of &lt;ulink linkType="Drug" linkID="44306"&gt;pentoxifyllin&lt;/ulink&gt; ointment and placebo in treatment of bedsore.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to receive either topical pentoxifyllin 5%  (formulated in the faculty of pharmacy affiliated to &lt;ulink linkType="Company" linkID="1043016"&gt;Tehran University of Medical Sciences&lt;/ulink&gt;)  or placebo ointment twice daily topically for 14 days. Grade of bedsore will be evaluated at baseline and after 14 days of interventions based on the 2-digit Stirling scale.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Imam Khomeini Hospital</Name><Address1>Tehran</Address1><Contacts><Contact type="Facility contact"><Name>Hossein Khalili</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other dermatological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17864">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16004">Subjects with Skin Ulcer</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201402233449N16</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other dermatological disease" id="43234"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other dermatological disease" id="43369"><Endpoint>Assessment of Clinical Symptoms</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other dermatological disease" id="32830"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="33233"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other dermatological disease" id="24216"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2016-02-29T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>25.00 Months</EnrollmentPeriod><EnrollmentRate>4.00 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-08-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="36247"><TitleDisplay>A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-Month Period</TitleDisplay><TitleOfficial>Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for 6 Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">TXA110948</Identifier><Identifier type="Organisational Study">110948</Identifier><Identifier type="NCT">NCT00792636</Identifier></Identifiers><Indications><Indication id="148">Headache</Indication><Indication id="210">Migraine</Indication></Indications><BiomarkerNames><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Therapeutic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Name><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>naproxen sodium</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>sumatriptan</Name><Drug id="4491">sumatriptan</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><IndicationsPioneer><Indication id="148">Headache</Indication></IndicationsPioneer><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="31482" type="Drug"><TargetEntity id="297297" type="siDrug">Sumatriptan succinate/naproxen sodium</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="148" type="ciIndication"><TargetEntity id="R51" type="ICD10"></TargetEntity><TargetEntity id="784.0" type="ICD9"></TargetEntity><TargetEntity id="10019211" type="MEDDRA"></TargetEntity><TargetEntity id="D006261" type="MeSH"></TargetEntity><TargetEntity id="-843303252" type="omicsDisease"></TargetEntity><TargetEntity id="25" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"></TargetEntity><TargetEntity id="10027599" type="MEDDRA"></TargetEntity><TargetEntity id="D008881" type="MeSH"></TargetEntity><TargetEntity id="-672899670" type="omicsDisease"></TargetEntity><TargetEntity id="27" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="10" type="Action"><TargetEntity id="222" type="Mechanism">5-HT1D Agonists</TargetEntity></SourceEntity><SourceEntity id="8" type="Action"><TargetEntity id="221" type="Mechanism">5-HT1B Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>49</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10">5-HT 1d receptor agonist</Action><Action id="8">5-HT 1b receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2946">Analgesic</Class><Class id="2955">Non-steroidal anti-inflammatory</Class><Class id="726">Vasoconstrictor</Class></Class><Technologies><Technology id="175">Drug combination</Technology><Technology id="751">Film coating</Technology><Technology id="605">Nasal systemic formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="661">Oral quick release formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>407</PatientCountEnrollment><PatientCountEvaluable>352</PatientCountEvaluable><DateStart>2008-11-30T00:00:00Z</DateStart><DateEnd type="actual">2009-11-30T00:00:00Z</DateEnd><DateChangeLast>2017-11-27T04:51:37Z</DateChangeLast><DateAdded>2008-11-19T11:40:08Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and female outpatients 18 to 65 years of age. Female subjects are eligible for
             participation in the study if they are:&lt;ul&gt;&lt;li&gt;Females of non-childbearing potential&lt;/li&gt;&lt;li&gt;Females of childbearing potential and who have a negative urine pregnancy test at
                  screening and   agree to use one of the&lt;ulink linkType="Company" linkID="28355"&gt;GlaxoSmithKline&lt;/ulink&gt; specified highly
                  effective methods for avoiding pregnancy.  Subjects taking oral contraceptives
                  must be on a stable regimen for at least 2 months prior to screening&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subject with migraines, with or without aura (ICHD-II criteria, 1.2.1 or 1.1)
             [International Headache Society, 2004]. Subject must have a history of two to eight
             attacks per month, on average, for the 6 months prior to the screening visit.
             Additionally the subject is to have experienced at least two, but no more than eight,
             migraine attacks per month for the 3 months prior to screening visit&lt;/li&gt;&lt;li&gt;Subject is able to distinguish migraine attacks from other headaches (ie,
             tension-type headaches)&lt;/li&gt;&lt;li&gt;Subject is willing and able to provide written informed consent, to comprehend and
             perform the requirements of the protocol&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject has &gt;/=10 migraine attacks or &gt;/= 15 headache days per month in total (including
             migraine, probable migraine or tension-type headache)&lt;/li&gt;&lt;li&gt;Subject has retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine
             (ICHD-II 1.2.4), or secondary headaches [International Headache Society, 2004]&lt;/li&gt;&lt;li&gt;Subject has a history of controlled or uncontrolled hypertension or is currently
             taking any angiotension-converting enzyme (ACE) inhibitor or angiotension receptor
             blocker&lt;/li&gt;&lt;li&gt;Subject has an in-clinic screening blood pressure of &gt;/= 130/85  mmHg in two out of three
             blood pressure measurements&lt;/li&gt;&lt;li&gt;Subject is taking any anti-hypertensive medication for any reason including for
             migraine prophylaxis&lt;/li&gt;&lt;li&gt;Subject has a glycosylated hemoglobin &gt;/= 8.0&lt;/li&gt;&lt;li&gt;Subject has a chronic condition (ie, osteoarthritis, rheumatoid
             arthritis,fibromyalgia) which requires chronic daily administration of non-steroidal
             anti-inflammatory drugs (NSAIDS) (including acetaminophen) or opioids or opioid
             combination products&lt;/li&gt;&lt;li&gt;Subject, in the investigator's opinion, is likely to have unrecognized cardiovascular
             or cerebrovascular disease&lt;/li&gt;&lt;li&gt;Subject has a history of congenital heart disease, cardiac arrhythmias requiring
             medication, or a history of a clinically significant electrocardiogram abnormality
             that, in the investigator's opinion, contraindicates participation in the study&lt;/li&gt;&lt;li&gt;Subject has evidence or history of any ischemic vascular diseases including: ischemic
             heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's
             Syndrome, or any signs or symptoms consistent with any of the above&lt;/li&gt;&lt;li&gt;Subject has evidence or history of central nervous system pathology including stroke
             and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which
             lower the convulsive threshold, or has been treated with an antiepileptic drug for
             seizure control within five years prior to Screening&lt;/li&gt;&lt;li&gt;Subject has a history of impaired hepatic or renal function that, in the
             investigator's opinion, contraindicates participation in the study&lt;/li&gt;&lt;li&gt;Subject has hypersensitivity, allergy, intolerance or contraindication to the use of
             any triptan, NSAID, or aspirin (including all&lt;ulink linkType="Drug" linkID="31482"&gt;sumatriptan + naproxen&lt;/ulink&gt; preparations)
             or has nasal polyps and asthma&lt;/li&gt;&lt;li&gt;Subject is currently taking, or has used, an ergot or ergot-derived medication in the
             previous three months for migraine prophylaxis or is taking a medication that is not
             stabilized (ie, change of a dose within the past 2 months) for chronic or
             intermittent migraine prophylaxis or for a co-morbid condition that is not
             stabilized&lt;/li&gt;&lt;li&gt;Subject has a recent history of regular use of opioids or barbiturates for the
             treatment of their migraine headache and/or other non-migraine pain. Regular use is
             defined as an average of 4 days per month over the last 6 months&lt;/li&gt;&lt;li&gt;Subject has taken or plans to take a monoamine oxidase inhibitor (MAOI), including
             herbal preparations containing St John's Wort (Hypericum perforatum) or a CNS
             stimulant medication (such as atomoxetine, dextroamphetamine and amephetamine
             products, dexmethlyphenidate, lisdexamdetamine dimesylate and methylphenidate) anytime
             within two weeks prior to screening through 2-weeks post-treatment&lt;/li&gt;&lt;li&gt;Subject has a history of any bleeding disorder or is currently taking any
             anticoagulant or any anti-platelet agent. (except low-dose aspirin&amp;lt;/= 325 mg/day for
             cardioprotective reasons)&lt;/li&gt;&lt;li&gt;Subject has evidence or history of any gastrointestinal surgery, gastrointestinal
             ulceration or perforation in the past 6 months, gastrointestinal bleeding in the
             past year, or evidence or history of inflammatory bowel disease&lt;/li&gt;&lt;li&gt;Subject is pregnant, actively trying to become pregnant, or breast feeding or subject
             is not willing to have pregnancy tests performed as required&lt;/li&gt;&lt;li&gt;Subject tests positive for illicit substances on toxicology screen or has evidence of
             alcohol or substance abuse within the last year, or any concurrent medical or
             psychiatric condition which, in the investigator's judgment, will likely interfere
             with the study conduct, subject cooperation, or evaluation and interpretation of the
             study results, or which otherwise contraindicates participation in this clinical
             trial&lt;/li&gt;&lt;li&gt;Subject has participated in an investigational drug trial within the previous 4
             weeks or plans to participate in another study at any time during the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen: the calculation of baseline and post-baseline mean blood pressure (BP) (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM)</Description><Timeframe>Baseline and Month 6</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen: the calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM)</Description><Timeframe>Baseline and Month 6</Timeframe></Measure><Measure><Description>Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan: the calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM)</Description><Timeframe>Baseline and Month 6</Timeframe></Measure><Measure><Description>Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen: the calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM)</Description><Timeframe>Baseline and Month 6</Timeframe></Measure><Measure><Description>Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, &lt; 4 Migraines, 4 to 6 Migraines, &gt;/= 4 Migraines, and &gt; 6 Migraines Per Month: he calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis. LSMeans and corresponding confidence intervals were not calculated for &gt; 6 migraines/month group due to lack of convergence</Description><Timeframe>Baseline and Month 6</Timeframe></Measure><Measure><Description>Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, &lt; 1.3 Times Per Migraine, 1.3 to 1.7 Times Per Migraine, and &gt; 1.7 Times Per Migraine: the calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis</Description><Timeframe>Baseline and Month 6</Timeframe></Measure><Measure><Description>Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With &lt; 6, 6 to 10, &gt;/= 6, 10 to 14, and &gt; 14 Doses Per Month: the calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 60-90 and the &gt;90 total dose groups due to lack of convergence</Description><Timeframe>Baseline and Month 6</Timeframe></Measure><Measure><Description>Number of Participants With an Increase of &gt;/= 5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements: the number of participants with an increase of &gt;=5 mmHg from the baseline systolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 h after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine</Description><Timeframe>Baseline to End of Study (6-month study duration)</Timeframe></Measure><Measure><Description>Number of Participants With an Increase of &gt;/=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements: the number of participants with an increase of &gt;/= 3 mmHg from the baseline diastolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 h after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine</Description><Timeframe>Baseline to End of Study (6-month study duration)</Timeframe></Measure><Measure><Description>Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of &gt;/= 140 mmHg During the Study: the number of participants with any valid two-day consecutive average systolic blood pressure measurement of &gt;/= 140 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 h following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 h after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine</Description><Timeframe>Baseline to End of Study (6-month study duration)</Timeframe></Measure><Measure><Description>Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of &gt;/= 90 mmHg: the number of participants with any valid two-day consecutive average diastolic blood pressure measurement of &gt;/= 90 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 h following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 h after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine</Description><Timeframe>Baseline to End of Study (6-month study duration)</Timeframe></Measure><Measure><Description>Time to the First Day With an Average Systolic Blood Pressure Increase of &gt;/= 5 mmHg From the Baseline Systolic Blood Pressure: Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of &gt;/= 3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 h following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 h after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine</Description><Timeframe>Baseline to End of Study (6-month study duration)</Timeframe></Measure><Measure><Description>Time to the First Day With an Average Diastolic Blood Pressure Increase of &gt;/= 3 mmHg From the Baseline Diastolic Blood Pressure: Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of &gt;/= 3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 h following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 h after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine</Description><Timeframe>Baseline to End of Study (6-month study duration)</Timeframe></Measure><Measure><Description>Number of Participants Withdrawn From the Study Due to Blood Pressure Changes: the number of participants withdrawn from the study due to protocol-defined blood pressure changes were summarized for each treatment group. Defined blood pressure changes included (1) monthly average BP ≥140 mmHg systolic or &gt;=90 mmHg diastolic and confirmed in clinic, (2) monthly average BP increase of &gt;=30 mmHg systolic or &gt;/= 20 mmHg from in-clinic screening and confirmed in clinic, and (3) systolic &gt;/= 140 mmHg or diastolic &gt;/= 90 mmHg on consecutive clinic visits &gt;/= 2 weeks apart</Description><Timeframe>Baseline to End of Study (6-month study duration)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  purpose of this study was to test the effect on blood pressure of &lt;ulink linkType="Drug" linkID="31482"&gt;sumatriptan + naproxen
      sodium&lt;/ulink&gt; (Treximet) combination tablets, tablets containing only &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt;, and tablets containing only
      naproxen sodium when these drugs are taken to treat migraine headaches that occur during a
      6-month period.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results showed that  there was no rise in blood pressure in patients treated with &lt;ulink linkType="Drug" linkID="31482"&gt;sumatriptan + naproxen sodium&lt;/ulink&gt; up to 6 months. The small decrease in blood pressure observed in this study was not considered to be clinically relevant. A decrease in at-home  systolic and diastolic blood pressures from baseline to 6 months was observed for &lt;ulink linkType="Drug" linkID="31482"&gt;sumatriptan + naproxen sodium&lt;/ulink&gt; with a LSMean change of -2.1  and -1.5 mmHg, respectively. Similar results were observed for the changes from baseline to 6 months in at-home systolic and diastolic blood pressure for the &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt; and naproxen groups. The most commonly observed adverse events included in all three groups were nasopharyngitis, urinary tract infection, upper respiratory tract infection, dizziness, neck pain, nausea, somnolence, back pain, sinus congestion and seasonal allergy. None of the serious adverse events were considered by the investigator to be related to the study medication [&lt;ulink linkType="Reference" linkID="1203212"&gt;1203212&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive naproxen sodium at 500 mg or &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt; at  85 mg or the combination tablet.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received  &lt;ulink linkType="Drug" linkID="31482"&gt;sumatriptan   + naproxen sodium&lt;/ulink&gt; (85/500 mg    tablets) or  &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt; 85 mg  and naproxen sodium 500 mg  alone [&lt;ulink linkType="Reference" linkID="1203212"&gt;1203212&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionControl"><Name>naproxen sodium</Name><Dose unit="milligram dose">500.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="1009">Urinary tract infection</Indication><CountPatientsAffectedPercentage>2.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsAffectedPercentage>4.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3073">Drowsiness</Indication><CountPatientsAffectedPercentage>2.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3221">Back pain</Indication><CountPatientsAffectedPercentage>2.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="516">Upper respiratory tract infection</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Name><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="1009">Urinary tract infection</Indication></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3073">Drowsiness</Indication><CountPatientsAffectedPercentage>2.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3221">Back pain</Indication><CountPatientsAffectedPercentage>2.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionControl"><Name>sumatriptan</Name><Drug id="4491">sumatriptan</Drug><Dose unit="milligram dose">85.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="1009">Urinary tract infection</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>2.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3073">Drowsiness</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3221">Back pain</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="516">Upper respiratory tract infection</Indication><CountPatientsAffectedPercentage>4.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="74134">naproxen sodium</Intervention><Treatments><Treatment><Dose>500 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="74136">sumatriptan</Intervention><Treatments><Treatment><Dose>85 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Anaheim</Address1><Address2>California</Address2><Address3>92801</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Anaheim</Address1><Address2>California</Address2><Address3>92805</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30308</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78705</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Avon</Address1><Address2>Connecticut</Address2><Address3>06001</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Bristol</Address1><Address2>Tennessee</Address2><Address3>37620</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Buena Park</Address1><Address2>California</Address2><Address3>90620</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Chandler</Address1><Address2>Arizona</Address2><Address3>85224</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60614</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3>44122</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Colorado Springs</Address1><Address2>Colorado</Address2><Address3>80904</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Decatur</Address1><Address2>Georgia</Address2><Address3>30034</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Garden Grove</Address1><Address2>California</Address2><Address3>92845</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Gilbert</Address1><Address2>Arizona</Address2><Address3>85234</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Greensboro</Address1><Address2>North Carolina</Address2><Address3>27405</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Harrisburg</Address1><Address2>North Carolina</Address2><Address3>28075</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Hialeah</Address1><Address2>Florida</Address2><Address3>33010</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77004</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32216</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Kalamazoo</Address1><Address2>Michigan</Address2><Address3>49009</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Litchfield Park</Address1><Address2>Arizona</Address2><Address3>85340</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><Address3>72205</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Matthews</Address1><Address2>North Carolina</Address2><Address3>28105</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Memphis</Address1><Address2>Tennessee</Address2><Address3>38018</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33143</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Mount Pleasant</Address1><Address2>South Carolina</Address2><Address3>29464</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37203</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Newport Beach</Address1><Address2>California</Address2><Address3>92660</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73112</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Pembroke Pines</Address1><Address2>Florida</Address2><Address3>33024</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85050</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><Address3>15236</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Raleigh</Address1><Address2>North Carolina</Address2><Address3>27607</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Raleigh</Address1><Address2>North Carolina</Address2><Address3>27609</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Raleigh</Address1><Address2>North Carolina</Address2><Address3>27612</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Salt Lake City</Address1><Address2>Utah</Address2><Address3>84107</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78205</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Santa Monica</Address1><Address2>California</Address2><Address3>90404</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Simpsonville</Address1><Address2>South Carolina</Address2><Address3>29681</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Springfield</Address1><Address2>Missouri</Address2><Address3>65807</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3>63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>St. Petersburg</Address1><Address2>Florida</Address2><Address3>33702</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Sunrise</Address1><Address2>Florida</Address2><Address3>33351</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Tempe</Address1><Address2>Arizona</Address2><Address3>85283</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>West Chester</Address1><Address2>Ohio</Address2><Address3>45069</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>West Jordan</Address1><Address2>Utah</Address2><Address3>84088</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Westlake Village</Address1><Address2>California</Address2><Address3>91361</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67207</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><Address3>27103</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8399">Subjects with Migraine</PatientSegment><SubSegments><SubSegment id="8401">Subjects with migraine without aura</SubSegment><SubSegment id="8403">Subjects with migraine with aura</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00792636</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26009"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="26009"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26042">Assessment of drop-out rate/withdrawal rate</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22108"><Criterion>Subjects with Migraine</Criterion><SubCriteria><SubCriterion disease="Pain" id="22109">Subjects with migraine without aura</SubCriterion><SubCriterion disease="Pain" id="22111">Subjects with migraine with aura</SubCriterion><SubCriterion disease="Pain" id="22117">Subjects with episodic migraine</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20035"><Criterion>Subjects with Migraine</Criterion><SubCriteria><SubCriterion disease="Pain" id="20036">Subjects with migraine without aura</SubCriterion><SubCriterion disease="Pain" id="20039">Subjects with familial hemiplegic migraine</SubCriterion><SubCriterion disease="Pain" id="20040">Subjects with sporadic hemiplegic migraine</SubCriterion><SubCriterion disease="Pain" id="20041">Subjects with basilar migraine</SubCriterion><SubCriterion disease="Pain" id="20043">Subjects with chronic migraine</SubCriterion><SubCriterion disease="Pain" id="20045">Subjects with probable migraine</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20047"><Criterion>Subjects with Other Headaches</Criterion><SubCriteria><SubCriterion disease="Pain" id="20048">Subjects with tension-type headache [TTH]</SubCriterion><SubCriterion disease="Pain" id="20051">Subjects with headache attributed to a secondary cause</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20052"><Criterion>Subjects with Somatic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="20054">Subjects with fibromyalgia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20095"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="20097">Subjects with pre-specified vital signs</SubCriterion><SubCriterion disease="Pain" id="20111">Subjects with abnormal/unacceptable metabolic function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20122">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20118"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Pain" id="20119"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20120"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20132">Subjects with history/scheduled to receive opioids</SubCriterion><SubCriterion disease="Pain" id="20133">Subjects with history of NSAIDs</SubCriterion><SubCriterion disease="Pain" id="20134">Subjects with history/scheduled to receive acetaminophen</SubCriterion><SubCriterion disease="Pain" id="20137">Subjects with history/scheduled to receive anti-depressants</SubCriterion><SubCriterion disease="Pain" id="20138">Subjects with history/scheduled to receive anti-convulsants</SubCriterion><SubCriterion disease="Pain" id="20146">Subjects with history/scheduled to receive ergot alkaloids</SubCriterion><SubCriterion disease="Pain" id="20150">Subjects with history/scheduled to receive angiotensin converting enzyme (ACE) inhibitors</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion><SubCriterion disease="Pain" id="20177">Subjects with history/scheduled to undergo surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25794"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20155">Subjects with history/scheduled to receive dietary/herbal supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26300"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Pain" id="20105">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Pain" id="20106">Subjects with abnormal/unacceptable renal function</SubCriterion><SubCriterion disease="Pain" id="20108">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-11-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2009-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>5.06 Months</EnrollmentPeriod><EnrollmentRate>80.43 Patients/Month</EnrollmentRate><DateFirstReceived>2008-11-17T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-11-19T11:40:08Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="49692"><TitleDisplay>A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer</TitleDisplay><TitleOfficial>A Phase II Study of Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB or IV) Other Than Predominantly Squamous Cell Histology</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">2008-004330-24</Identifier><Identifier type="Organisational Study">10726</Identifier><Identifier type="NCT">NCT00867009</Identifier><Identifier type="Secondary Organisational">H3E-MC-S104</Identifier><Identifier type="Trial Acronym">S104</Identifier></Identifiers><Indications><Indication id="3665">Metastatic non small cell lung cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cetuximab</Name><Drug id="10388">cetuximab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>pemetrexed disodium</Name><Drug id="3536">pemetrexed disodium</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10388">cetuximab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3536">pemetrexed disodium</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3536" type="Drug"><TargetEntity id="173565" type="siDrug">Pemetrexed disodium</TargetEntity></SourceEntity><SourceEntity id="10388" type="Drug"><TargetEntity id="230562" type="siDrug">Cetuximab</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"></TargetEntity><TargetEntity id="613" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="135" type="Action"><TargetEntity id="413" type="Mechanism">Dihydrofolate Reductase (DHFR) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="181" type="Action"><TargetEntity id="432" type="Mechanism">Glycinamide Ribonucleotide Formyltransferase (GARTFase) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>26</NumberOfSites><CompaniesSponsor><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="135">DHFR inhibitor</Action><Action id="181">GAR transformylase inhibitor</Action><Action id="372">Thymidylate synthase inhibitor</Action><Action id="374">Transferase inhibitor</Action><Action id="740">Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2946">Analgesic</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class><Class id="805">Folate modulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="167">Monoclonal antibody murine</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>113</PatientCountEnrollment><DateStart>2009-04-30T00:00:00Z</DateStart><DateEnd type="actual">2014-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-06-20T06:04:23Z</DateChangeLast><DateAdded>2009-03-24T06:57:05Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient must sign an informed consent document for clinical and translational research&lt;/li&gt;&lt;li&gt;Patient must have histological diagnosis of locally advanced or metastatic (stage IIIB [not amenable to curative treatment] or IV NSCLC other than predominantly squamous cell histology [referred to as 'nonsquamous'] NSCLC)&lt;/li&gt;&lt;li&gt;Patients must have biological tissue available from their diagnosis tumor for detection of some biomarkers eg, EGFR expression (translational research)&lt;/li&gt;&lt;li&gt;Patients cannot be receiving nor have received any prior systemic anticancer therapy, immunotherapy, targeted therapy, or biological therapy for their lung cancer (except chemotherapy given after surgery if it has been completed &gt; 1 year before the study entry)&lt;/li&gt;&lt;li&gt;Prior chest irradiation is allowed provided it was terminated at least 12 weeks prior to study entry&lt;/li&gt;&lt;li&gt;Patient is allowed to have had prior radiation therapy as long as it was&amp;lt;/= 25% of the bone marrow and did not include the whole pelvis. Prior radiation therapy should be completed at least 2 weeks prior to first study drug. Thoracic radiation must be completed &gt; 12 weeks before the study entry. Patient must be recovered from the toxic effects of radiation therapy prior to day 1 of cycle 1&lt;/li&gt;&lt;li&gt;Patient must have at least one  measurable tumor lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Target lesions must not be in an irradiated area&lt;/li&gt;&lt;li&gt;Males and females at least 18 years of age&lt;/li&gt;&lt;li&gt;Patients must have a performance status of 0 or 1 on the ECOG scale&lt;/li&gt;&lt;li&gt;Patients must have adequate organ function as follows:&lt;ul&gt;&lt;li&gt;Adequate bone marrow reserve:&lt;ul&gt;&lt;li&gt;White blood cell count &gt;/= to 3 x 10(9)/l&lt;/li&gt;&lt;li&gt;Absolute neutrophil (segmented and bands) count &gt;/= 1.5 x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100 x 10(9)/l, and&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 9.0 g/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;Bilirubin&amp;lt;/= 1.5 x upper limit of normal (ULN&lt;/li&gt;&lt;li&gt;Alkaline phosphatase, alanine transaminase, and aspartate transaminase&amp;lt;/= 2.5 x ULN (&amp;lt;/= 5 x ULN with liver metastases)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal:&lt;ul&gt;&lt;li&gt;Creatinine&amp;lt;/= 1.5 x ULN, and&lt;/li&gt;&lt;li&gt;Calculated creatinine clearance &gt;/= 45ml/min based on the Cockcroft-Gault formula (Cockcroft and Gault 1976). These tests must be performed within 7 days prior to day 1 of cycle 1.&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients must at least be able to be physically mobile, take care of themselves, and must be up and about and able to perform light activities such as light housework or office work&lt;/li&gt;&lt;li&gt;Test results assessing the function of blood forming tissue, kidneys, and liver must be satisfactory&lt;/li&gt;&lt;li&gt;Females must be:&lt;ul&gt;&lt;li&gt;Sterile: are women not of childbearing potential due to surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)&lt;/li&gt;&lt;li&gt;Postmenopausal: are defined as women of age &gt;/= 45 with an intact uterus who have not taken hormones or oral contraceptives within the last 6 months/year who have had either cessation of menses for at least one year, or 6 to 12 months of spontaneous amenorrhea with follicle stimulating hormone) (FSH) &gt; 40 mIU/ml&lt;/li&gt;&lt;li&gt;On contraception: women of childbearing potential who test negative for pregnancy at the time of enrollment based on a serum or urine pregnancy test within 7 days prior to day 1 of cycle 1, and agree to use a reliable method of birth control during the study and for 6 months following the last dose of study drug&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Males must be on contraception or sterile (for example post-vasectomy) during the study and for 6 months following the last dose of study drug&lt;/li&gt;&lt;li&gt;Patients must have an estimated life expectancy of at least 12 weeks&lt;/li&gt;&lt;li&gt;Patients are able to comply with study and/or follow-up procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient cannot have symptomatic central nervous system metastases&lt;/li&gt;&lt;li&gt;Patients cannot have an active infection or other serious condition (eg, tuberculosis or active infection including human immunodeficiency [HIV] syndrome) that their doctor thinks would make you unable to participate&lt;/li&gt;&lt;li&gt;Patient cannot have a serious cardiac condition, such as a heart attack, angina, or heart disease, as defined by the New York Heart Association Class II, III, or IV, within 6 months of entering the trial&lt;/li&gt;&lt;li&gt;Patient cannot have had a another form of cancer other than superficial basal cell and superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the last five years&lt;/li&gt;&lt;li&gt;Patient cannot have had significant neurological or psychiatric disorders including dementia, seizures and bipolar disorder&lt;/li&gt;&lt;li&gt;Patient cannot have moderate or severe peripheral neuropathy of CTCAE grade &gt;/= 1&lt;/li&gt;&lt;li&gt;Patient cannot have received treatment within 30 days prior to day 1 of cycle 1 with any experimental (any drug that has not received regulatory approval for any indication at the time of study entry)&lt;/li&gt;&lt;li&gt;Patient cannot have had a major surgery within the last 4 weeks prior to study entry&lt;/li&gt;&lt;li&gt;Patient cannot have previously received treatment with transduction inhibitors or Epidermal Growth Factor Receptor (EGFR)-targeting therapy&lt;/li&gt;&lt;li&gt;Patients cannot be receiving concurrent chronic systemic immune therapy, or chemotherapy for a disease other than cancer&lt;/li&gt;&lt;li&gt;Patient cannot have prior known allergic/hypersensitivity reaction to any of the components of study treatments&lt;/li&gt;&lt;li&gt;Females cannot be pregnant or breastfeeding&lt;/li&gt;&lt;li&gt;Patient is unable to stop taking &gt; 1.3 g of aspirin on a daily basis or other aspirin like medication (non-steroidal antiinflammatory drugs: NSAIDs) for a few days (a 5-day period for aspirin, or  a 8-day period for long-acting agents, such as piroxicam) during each cycle of therapy&lt;/li&gt;&lt;li&gt;Patient is unable or unwilling to take folic acid, injections of vitamin B12, or corticosteroid supplementation&lt;/li&gt;&lt;li&gt;Patients cannot have fluid around their lungs or in their abdomen (pleural effusions or ascites) that cannot be controlled by drainage or other procedures prior to day 1 of cycle 1&lt;/li&gt;&lt;li&gt;Patient cannot have known drug abuse&lt;/li&gt;&lt;li&gt;Patient cannot have received a yellow fever vaccination within the previous 30 days or plan to have it&lt;/li&gt;&lt;li&gt;Patients cannot be investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted&lt;/li&gt;&lt;li&gt;Patients cannot be Eli Lilly employees&lt;/li&gt;&lt;li&gt;Patients must not be currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The primary objective of this study is to assess the antitumor activity of the combination therapy of pemetrexed and cisplatin plus cetuximab, as measured by the objective response rate (ORR), in patients with Stage IIIB or IV nonsquamous NSCLC</Description></Measure><Measure><Description>The primary outcome measure for this trial is ORR, based on the patient's best response across all study treatment cycles. Investigators will determine the cycle response using RECIST criteria. The ORR will be the proportion of the PQ patient population having a confirmed response of PR or CR. The ORR will be estimated for the PQ patient population using unadjusted, large-sample, normal approximation for binomial proportions (z approximation). The RR will be compared to historical control data on pemetrexed and cisplatin without cetuximab administered to a similar patient population</Description></Measure><Measure><Description>Percentage of patients With a tumor response (Objective Tumor Response Rate): response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR) = disappearance of all target lesions, Partial Response (PR) = 30% decrease in sum of longest diameter of target lesions. Tumor response is presented as a percentage (%) and is the number of patients with a CR plus PR divided by the number of patients in the protocol qualified (PQ) population, then multiplied by 100</Description><Timeframe>From start of treatment until documented best response (up to 18.9 months)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Progression-free survival (PFS): PFS is measured from study entry until disease progression, death or date of last contact. Progressive disease (PD) was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions or the appearance of &gt;/= 1 new lesions and/or unequivocal progression of existing non-target lesions. For patients not known to have died or have had objective PD as of the data cutoff date, PFS was censored at the date of the last objective progression-free disease assessment</Description><Timeframe>From start of treatment until documented disease progression or death from any cause (up to 18.9 months)</Timeframe></Measure><Measure><Description>The percentage of patients still living at one year (One Year Survival Rate): the one year survival rate is presented as percentage (%) of patients still living at one year and is the number of patients that are still alive at one year divided by the number of patients in the protocol qualified (PQ) population, which is then multiplied by 100</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>The percentage of patients with Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]): the DCR is presented as percentage (%) and is the number of patients with a best tumor response of CR, PR, or SD divided by the number of patients in the protocol qualified (PQ) population, then multiplied by 100. Best tumor response of CR, PR, or SD was determined from the sequence of tumor response assessments. Tumor response was assessed using RECIST criteria. CR = disappearance of all target lesions; PR = 30% decrease in sum of longest diameter of target lesions; SD = small changes that do not meet above criteria</Description><Timeframe>From start of treatment until documented best tumor response (up to 18.9 months)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this open-label, non-randomized study was to  estimate the response rate in patients with advanced or metastatic
      non-squamous Non-Small Cell Lung Cancer, when treated with &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt; (Alimta or LY-231514) and cisplatin plus &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; followed by &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; maintenance therapy.&lt;/para&gt;&lt;para&gt;The primary objective of the trial was to estimate the objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.&lt;/para&gt;&lt;para&gt;The secondary objectives of the trial were:&lt;br/&gt;To estimate progression-free survival (PFS).&lt;br/&gt;To estimate one-year survival rate.&lt;br/&gt;To examine the safety and toxicity profile of study treatment.&lt;br/&gt;To assess biomarkers relevant for &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;.&lt;br/&gt;To explore the correlation between biomarkers and clinical outcome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this study, patients who don't progress after  four to six cycles of
      induction treatment with &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt;, cisplatin and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; would receive maintenance
      treatment with &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;. &lt;br/&gt;&lt;ulink linkType="Drug" linkID="3536"/&gt;&lt;ulink&gt;Pemetrexed&lt;/ulink&gt;: induction therapy: 500 mg/m2, iv, on day 1 of each 21-day cycle for four to six cycles. Maintenance therapy: 500 mg/m2, iv, on day 1 of each 21-day cycle until progressive disease or treatment discontinuation.&lt;br/&gt;Cisplatin: induction therapy: 75 mg/m2, iv, on day 1 of each 21-day cycle for four to six cycles.&lt;br/&gt;&lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt;: induction therapy: loading dose of 400 mg/m2, iv, on day 1 of cycle 1, then 250 mg/m2, iv, weekly for four to six 21-day cycles. Maintenance therapy: 250 mg/m2, iv, weekly until progressive disease or treatment discontinuation.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Wels</Address1><Address3>4600</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Graz</Address1><Address3>8036</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Salzburg</Address1><Address3>5020</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Homburg</Address1><Address3>66421</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Berlin</Address1><Address3>13125</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Halle</Address1><Address3>D-06120</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Mannheim</Address1><Address3>68167</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Tuebingen</Address1><Address3>72076</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Barcelona</Address1><Address3>08003</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Lleida</Address1><Address3>25198</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Madrid</Address1><Address3>28034</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Reus</Address1><Address3>43201</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Greece"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Athens</Address1><Address3>11527</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Patras</Address1><Address3>26500</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Bari</Address1><Address3>70126</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Potenza</Address1><Address3>85028</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Torino</Address1><Address3>10100</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Bergamo</Address1><Address3>24128</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Palermo</Address1><Address3>90146</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Treviso</Address1><Address3>31100</Address3><Contacts></Contacts></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>S-Hertogenbosch</Address1><Address3>5211 NL</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Amsterdam</Address1><Address3>1081 HV</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Groningen</Address1><Address3>9713 GZ</Address3><Contacts></Contacts></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Maastricht</Address1><Address3>6229 HX</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3617">Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><SubSegments><SubSegment id="7877">Subjects with non-squamous cell lung cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3623">Subjects with Advanced Stage Lung Cancer</PatientSegment><SubSegments><SubSegment id="3634">Subjects with metastatic/stage IV lung cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="12053">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00867009</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2008-004330-24</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8504"><Endpoint>Assessment of Objective Response</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8505">Assessment of objective response rate(ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8481"><Endpoint>Assessment of Overall Survival (OS)</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8483">Assessment of global/overall survival at 1 year</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8489"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8555"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8640">Adverse events as graded by CTCAE/CTC</SubEndpoint><SubEndpoint disease="Lung tumor" id="8642">Assessment of gastrointestinal toxicities (Upper and Lower)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lung tumor" id="8605"><Endpoint>Assessment of Oncogenes/Oncoproteins</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8608">Assessment of EGFR mutation/ amplification status</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Lung tumor" id="44828"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8513">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Lung tumor" id="8519">Assessment of Tumor Growth Control Rate (TGCR)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3900"><Criterion>Subjects with Non Small Cell Lung Cancer (NSCLC)</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3913"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3914">Subjects with measurable disease as per RECIST criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3925"><Criterion>Subjects with Protocol Specified Stages of Lung Cancer(TNM staging)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3938">Subjects with advanced stage lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3940"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3975"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Inclusion><Inclusion disease="Lung tumor" id="3987"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3988"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3989">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Lung tumor" id="3994">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4073"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4098">Subjects recovered from all prior therapies and/or their toxic/adverse effects</SubCriterion><SubCriterion disease="Lung tumor" id="22381">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="33317"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4024">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34001"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4032">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34147"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4106">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34925"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4074">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5121"><Criterion>Subjects with Evidence of Metastasis</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5122">Subjects with symptomatic/uncontrolled metastases</SubCriterion><SubCriterion disease="Lung tumor" id="5125">Subjects with central nervous system metastases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5132"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5149"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5193"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5269"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5277">Subjects with history of/scheduled for biological therapy</SubCriterion><SubCriterion disease="Lung tumor" id="5345">Subjects with history of/scheduled to receive an investigational drug</SubCriterion><SubCriterion disease="Lung tumor" id="6783">Subjects with history of/scheduled for immunotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5291"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5365">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="6756"><Criterion>Subjects with History of/Scheduled for Other Cancer Therapies</Criterion></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5128">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20282"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="26717"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5363">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="27073"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5139">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="27883"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5349">Subjects unable/unwilling to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-05-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.06 Months</EnrollmentPeriod><EnrollmentRate>9.37 Patients/Month</EnrollmentRate><DateFirstReceived>2009-03-20T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-03-24T06:57:05Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-10-30T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="63839"><TitleDisplay>Study to Assess the Metabolism, Excretion and Pharmacokinetics of (14C) AZD-1981 in Healthy Male Volunteers</TitleDisplay><TitleOfficial>An Open, Single-Dose, Single-Center, Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of (14C) AZD-1981 in Healthy Male Volunteers</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">D9830C00006</Identifier><Identifier type="NCT">NCT01058447</Identifier><Identifier type="Trial Acronym">ADME</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="31">Asthma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>AZD-1981</Name><Drug id="48602">AZD-1981</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="48602">AZD-1981</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="14190">AstraZeneca plc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="48602" type="Drug"><TargetEntity id="360639" type="siDrug">AZD-1981</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"></TargetEntity><TargetEntity id="D029424" type="MeSH"></TargetEntity><TargetEntity id="-459670493" type="omicsDisease"></TargetEntity><TargetEntity id="277" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="318" type="Action"><TargetEntity id="276" type="Mechanism">Prostanoid Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="14190">AstraZeneca plc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="11626">G-protein coupled receptor-44 antagonist</Action><Action id="318">Prostanoid receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioavailability</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>4</PatientCountEnrollment><DateStart>2010-02-28T00:00:00Z</DateStart><DateEnd type="actual">2010-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-07T05:02:36Z</DateChangeLast><DateAdded>2010-02-04T06:51:43Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>AstraZeneca R&amp;D, Lund, Sweden</Affiliation><Name>Eva S Pettersson</Name></Contact><Contact type="Scientific contact"><Affiliation>Quintiles Drug Research Unit at Guy´s Hospital, London, United Kingdom</Affiliation><Name>Tim Mant, Professor</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provision of signed, written and dated informed consent prior to any study specific
             procedure&lt;/li&gt;&lt;li&gt;Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Exposed to radiation levels above background of&amp;gt; 5 mSv in the last year, &amp;gt; 10 mSv over
             the last five years or a cumulative total of &amp;gt; 1 mSv per year of life&lt;/li&gt;&lt;li&gt;History or presence of any clinically significant disease or disorder in the opinion
             of the investigator&lt;/li&gt;&lt;li&gt;Any clinically relevant abnormal findings in physical examination, clinical
             chemistry, hematology, urinalysis, vital signs or ECG at baseline in the opinion of
             the investigator&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pharmacokinetic variables and Radioactivity</Description><Timeframe>Frequent sampling occasions during study days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety variables (ECG, adverse events, blood pressure, pulse, body temperature, safety lab)</Description><Timeframe>Frequent sampling occasions during study days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to characterize the absorption, distribution, metabolism and
      excretion (ADME) of a single oral dose of (14C) &lt;ulink linkType="Drug" linkID="48602"&gt;AZD-1981&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive a single dose of &lt;ulink linkType="Drug" linkID="48602"&gt;AZD-1981&lt;/ulink&gt; 250 mg, po tablet.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01058447</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4495"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4483"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4540"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4550"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4551">Blood pressure assessment</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4554">Temperature changes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4555"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4557">Electrographic evaluation</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3076"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3194"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="6974"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20271"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20278"><Criterion>Subjects with Abnormal Findings on Physical Assessments/Exercise Test</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="estimated">2010-03-24T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>0.90 Months</EnrollmentPeriod><EnrollmentRate>4.44 Patients/Month</EnrollmentRate><DateFirstReceived>2010-01-26T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-02-04T06:51:43Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="73618"><TitleDisplay>Comparison of NN-5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes</TitleDisplay><TitleOfficial>A Trial Comparing Efficacy and Safety of NN-5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">NN5401-3896</Identifier><Identifier type="NCT">NCT01272193</Identifier><Identifier type="Secondary Organisational">U1111-1118-0124</Identifier><Identifier type="Secondary Organisational">111385</Identifier><Identifier type="Other">JapicCTI-111385</Identifier><Identifier type="Trial Acronym">BOOST: JAPAN</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>insulin degludec + insulin aspart</Name><Drug id="55898">insulin degludec + insulin aspart</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>insulin glargine</Name><Drug id="10252">insulin glargine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="55898">insulin degludec + insulin aspart</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18614">Novo Nordisk A/S</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="55898" type="Drug"><TargetEntity id="419438" type="siDrug">Insulin degludec/insulin aspart</TargetEntity></SourceEntity><SourceEntity id="18614" type="Company"><TargetEntity id="4295865996" type="organizationId">Novo Nordisk A/S</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3a Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>50</NumberOfSites><CompaniesSponsor><Company id="18614">Novo Nordisk A/S</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="38212">Human insulin intermediate acting product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="805">Daily dosing</Technology><Technology id="175">Drug combination</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>296</PatientCountEnrollment><PatientCountEvaluable>296</PatientCountEvaluable><DateStart>2011-01-31T00:00:00Z</DateStart><DateEnd type="actual">2011-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-11-27T04:23:06Z</DateChangeLast><DateAdded>2011-01-11T03:51:32Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Development Division R &amp; D quality section</Affiliation><Email>seim@novonordisk.com</Email><Name>Novo Nordisk</Name></Contact><Contact type="Scientific contact"><Affiliation>Novo Nordisk A/S</Affiliation><Name>Global Clinical Registry (GCR, 1452)</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months&lt;/li&gt;&lt;li&gt;HbA1c 7.0 to 10.0% (both inclusive) by central laboratory analysis&lt;/li&gt;&lt;li&gt;Body Mass Index (BMI)&amp;lt;/= 35.0 kg/m2&lt;/li&gt;&lt;li&gt;Insulin naive subject and ongoing treatment with one or more oralantidiabetic drugs (OADs) for at least 12 weeks
             prior to randomization (visit 2/week 0) with at least recommended maintenance dose
             according to local, approved labelling. Allowed are:&lt;ul&gt;&lt;li&gt;Previous short term insulin treatment up to 14 days&lt;/li&gt;&lt;li&gt;Treatment during hospitalization or during gestational diabetes is allowed for periods &gt; 14 days)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Anticipated change in concomitant medication known to interfere significantly with
             glucose metabolism, such as systemic corticosteroids, beta-blockers, mono amino oxidase (MAO) inhibitors&lt;/li&gt;&lt;li&gt;Use of glucagon-like peptide-1 (GLP-1) receptor agonists, buformine and/or
             rosiglitazone within the last 12 weeks prior to randomization (visit 2/week 0)&lt;/li&gt;&lt;li&gt;Cardiovascular disease within the last 6 months prior to screening (visit 1) defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in Glycosylated Hemoglobin (HbA1c): observed change from baseline in HbA1c after 26 weeks of treatment</Description><Timeframe>Week 0 and 26</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean increment of nine-point self measured plasma glucose profile (SMPG) at the main evening meal: observed mean increment of the 9-point self-measured plasma glucose profile (SMPG) at the main evening meal</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Rate of treatment emergent Adverse Events (AEs): corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, persistent/significant disability/incapacity/congenital anomaly/birth defect</Description><Timeframe>Week 0 to 26 + 7 days follow up</Timeframe></Measure><Measure><Description>Rate of confirmed hypoglycemic episodes: observed rate of confirmed hypoglycemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycemic episodes consisted of severe hypoglycemia as well as minor hypoglycemic episodes. Severe hypoglycemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/l</Description><Timeframe>Week 0 to 26 + 7 days follow up</Timeframe></Measure><Measure><Description>Rate of nocturnal confirmed hypoglycemic episodes: observed rate of confirmed hypoglycemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycemic  episodes consisted of severe hypoglycemia as well as minor hypoglycemic  episodes. Severe hypoglycemic  episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycemic  episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/l. Nocturnal hypoglycemic  episodes were defined as occurring between 00:01 and 05:59 a.m</Description><Timeframe>Week 0 to 26 + 7 days follow up</Timeframe></Measure><Measure><Description>Change in body weight: observed change from baseline in body weight after 26 weeks of treatment</Description><Timeframe>Weeks 0, 26</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; showed good safety and tolerability profile. No apparent differences in adverse events and standard safety parameters were reported between the treatment groups. A total of 44% of patients in both groups experienced at least one hypoglycemic event but there was no severe hypoglycemia reported in either arm. The rates of adverse events were similar between both groups and eight patients reported a serious adverse event. Increases in body weight were similar in both groups (approximately 0.7 kg) [&lt;ulink linkType="Reference" linkID="1237270"&gt;1237270&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1328126"&gt;1328126&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, results were published from 18 randomized, controlled studies. Between two treatment strategies, no significant difference was observed in the rates of adverse events including total mortality and cardiovascular events [&lt;ulink linkType="Reference" linkID="2037446"&gt;2037446&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the trial was to investigate the efficacy and
      safety of &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; in patients with type 2 diabetes in Japan. Depending
      on pre-trial OADs, patients would continue at the same dose and dosing frequency.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2011, results were published. &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; was significantly superior to &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; in reducing HbA1c. HbA1c was reduced by approximately 1.4 and 0.3 percentage points for &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt;, respectively. &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; was associated with a trend of  lower risk hypoglycemia; the rate of confirmed hypoglycemic episodes was 27% lower for &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; when compared to &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt;. In addition, the rate of confirmed nocturnal hypoglycemic episodes was 25% lower for &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; in comparison to &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1237270"&gt;1237270&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, results were presented. The mean HbA1c value was 7.3% for &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt;, compared with 7% for &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; and the fasting plasma glucose levels were 5.6 and 5.7 mM/l, respectively. The proportion of patients achieving HbA1c &amp;lt; 7% with no hypoglycemia was 43.3 and 25% of &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt;-treated patients, respectively [&lt;ulink linkType="Reference" linkID="1328126"&gt;1328126&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2018, results were published from a meta-analysis of 18 randomized, controlled studies (&lt;ulink linkType="Protocol" linkID="7669"&gt;NCT00612040&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="8534"&gt;NCT00614055&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="60126"&gt;NCT00972283&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="30400"&gt;NCT00765817&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="60560"&gt;NCT00982228&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="64177"&gt;NCT01068678&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="64484"&gt;NCT01076647&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="61566"&gt;NCT01006291&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="64561"&gt;NCT01079234&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="64178"&gt;NCT01068665&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="63754"&gt;NCT01059799&lt;/ulink&gt;, NCT01272193, &lt;ulink linkType="Protocol" linkID="63312"&gt;NCT01045447&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="63308"&gt;NCT01045707&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="130076"&gt;NCT01849289&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="157442"&gt;NCT01959529&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="167468"&gt;NCT02034513&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="166798"&gt;NCT02030600&lt;/ulink&gt;) which aimed to assess the safety and efficacy of &lt;ulink linkType="Drug" linkID="59269"&gt;NN-1250&lt;/ulink&gt; versus insulin glargine in patients with type 1 (T1D) and type 2 (T2D) diabetes mellitus. A total of 16,791 patients were included. Irrespective of the pooled diabetic populations and follow-up durations, a a statistically significant reduction in risk for all confirmed hypoglycemia at the maintenance treatment period (estimated rate ratio [ERR] 0.81; p = 0.001), nocturnal confirmed hypoglycemia at the entire (ERR 0.71; p &amp;lt; 0.001) and maintenance treatment period (ERR 0.65; p &amp;lt; 0.001) was observed with NN-1250. Compared to T1D patients, the differences in the rate of hypoglycemia were found to be more pronounced in nocturnal period and maintenance period and in T2D. In T2D, the incidence of severe hypoglycemia (ERR 0.65; p = 0.005) was reduced with NN-1250, but not in T1D patients. Compared to insulin glargine, slightly higher HbA1c concentration was observed with NN-1250, but was not clinically relevant (estimated treatment difference [ETD] 0.03; p = 0.06). In NN-1250-treated patients, fasting plasma glucose level was found to be lower (ETD - 0.28 mmol/l; p = 0.001). Largely consistent findings were demonstrated by several sub-group analyses [&lt;ulink linkType="Reference" linkID="2037446"&gt;2037446&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of two arms:&lt;br/&gt;Arm A: patients would receive either  individually adjusted &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt; subcutaneously once daily prior to the largest meal of the day as monotherapy or combined with no more than two oral anti-diabetic drugs (OADs).&lt;br/&gt;Arm B: patients would receive individually adjusted &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt;  according to approved labelling either as monotherapy or combined with no more than two OADs.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized (1 : 1) to receive either &lt;ulink linkType="Drug" linkID="55898"&gt;NN-5401&lt;/ulink&gt;, or &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt;, both given once-daily with or without once-daily [&lt;ulink linkType="Reference" linkID="1237270"&gt;1237270&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>insulin degludec + insulin aspart</Name><Drug id="55898">insulin degludec + insulin aspart</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="2954">Weight gain</Indication></AdverseEvent><AdverseEvent><Indication id="445">Hypoglycemia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionControl"><Name>insulin glargine</Name><Drug id="10252">insulin glargine</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="2954">Weight gain</Indication></AdverseEvent><AdverseEvent><Indication id="445">Hypoglycemia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Asahikawa-shi, Hokkaido</Address1><Address3>070 0002</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Chigasaki-shi, Kanagawa</Address1><Address3>253 0052</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Chuo-ku, Tokyo</Address1><Address3>103 0002</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Chuo-ku, Tokyo</Address1><Address3>103 0027</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Ebina-shi</Address1><Address3>243 0432</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Fukuoka-shi, Fukuoka</Address1><Address3>815 8555</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Iruma-shi, Saitama</Address1><Address3>358 0003</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Izumisano-shi</Address1><Address3>598 0048</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kamakura-shi</Address1><Address3>247 0056</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kanagawa-shi, Yokohama</Address1><Address3>221 0802</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kashiwa-shi, Chiba</Address1><Address3>277 0825</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kashiwara-shi, Osaka</Address1><Address3>582 0005</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Katsushika-ku, Tokyo</Address1><Address3>125 0054</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kawagoe-shi, Saitama</Address1><Address3>350 0851</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kitakyushu-shi, Fukuoka</Address1><Address3>800 0252</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Koriyama-shi, Fukushima</Address1><Address3>963 8851</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kumamoto-shi, Kumamoto</Address1><Address3>861 8045</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kumamoto-shi,Kumamoto</Address1><Address3>862 0976</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kurume-shi, Fukuoka</Address1><Address3>830 8577</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kurume-shi, Fukuoka</Address1><Address3>839 0863</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kyoto-shi, Kyoto</Address1><Address3>615 8125</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Matsumoto-shi, Nagano</Address1><Address3>399 0006</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Miyazaki-shi</Address1><Address3>880 0034</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Naha-shi,</Address1><Address3>900 0032</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Naka-shi, Ibaraki</Address1><Address3>311 0113</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Nishinomiya-shi, Hygo</Address1><Address3>662 0971</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Obihiro-shi, Hokkaido</Address1><Address3>080 0016</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Obihiro-shi, Hokkaido</Address1><Address3>080 0848</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Ogawa-machi</Address1><Address3>355 0321</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Oita-shi</Address1><Address3>870 0039</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Okawa-shi, Fukuoka</Address1><Address3>831 0016</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Ota-ku, Tokyo</Address1><Address3>144 0035</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Oyama-shi, Tochigi</Address1><Address3>323 0022</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sapporo, Hokkaido</Address1><Address3>060 0033</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sapporo-shi, Hokkaido</Address1><Address3>060 0062</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sapporo-shi, Hokkaido</Address1><Address3>060-0001</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sapporo-shi, Hokkaido</Address1><Address3>062 0007</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sappro-shi, Hokkaido</Address1><Address3>060 8648</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sasebo-shi, Nagasaki</Address1><Address3>857 1165</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sendai-shi</Address1><Address3>980 0021</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Shimotsuke-shi, Tochigi</Address1><Address3>329 0433</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Shizuoka-shi</Address1><Address3>424 0853</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Tagajo-shi</Address1><Address3>985 0852</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Tagawa-shi, Fukuoka</Address1><Address3>825 8567</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Takatsuki-shi, Osaka</Address1><Address3>569 1096</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Tamana-shi, Kumamoto</Address1><Address3>865 0064</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Tokyo</Address1><Address3>167 0043</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Tsuchiura-shi, Ibaraki</Address1><Address3>300 0832</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Urasoe-shi,</Address1><Address3>901 2104</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Yokohama-shi, Kanagawa</Address1><Address3>227 0054</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="100">Subjects on Treatment/Requiring &gt;1  Antidiabetic Agent</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="102">Subjects with Good Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="103">Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="104">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="108">Subjects with obesity</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="145">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="172">Insulin Naive Type 2 Diabetes Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01272193</Identifier></Identifiers></Registry><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier type="Secondary Organisational">U1111-1118-0124</Identifier></Identifiers></Registry><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier>JapicCTI-111385</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1359">Change in HbA1c</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1346">Assessment of postprandial glucose</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1524">Frequency of hypoglycemic events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1503">Assessment of body weight</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="608"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="609">Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="610">Obese subjects (Grade 2 obesity, BMI= 30 to 39.9)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="670"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="1043"><Criterion>Non-Obese Subjects</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="1047"><Criterion>Treatment Naive Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1048">Insulin naïve subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="606">Subjects with Good Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="607">Subjects with Poor/Inadequate Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="901">Subjects with Moderate Glycemic Control</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="891"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="959"><Criterion>Conditions Altering Blood Glucose Levels</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="961">Subjects on glucocorticoid/steroid therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.03 Months</EnrollmentPeriod><EnrollmentRate>145.81 Patients/Month</EnrollmentRate><DateFirstReceived>2011-01-06T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-01-11T03:51:32Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="7467"><TitleDisplay>A Multicenter Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium (Macugen) Injected Into The Eye Every 6 Weeks For Up To Two Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension</TitleDisplay><TitleOfficial>A Phase II/III, Randomized, Controlled, Double-Masked, Multicenter, Comparative Trial, in Parallel-Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for Two Years, to Sham Injections in Subjects With Diabetic Macular Edema (DME) Involving the Center of the Macula With An Open-Label Macugen Year Three Extension</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">EOP1013H</Identifier><Identifier type="NCT Alias">NCT00148811</Identifier><Identifier type="Organisational Study">A5751013</Identifier><Identifier type="NCT">NCT00605280</Identifier></Identifiers><Indications><Indication id="2659">Diabetic macular edema</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pegaptanib</Name><Drug id="17475">pegaptanib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Standard of Care</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17475">pegaptanib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17475" type="Drug"><TargetEntity id="264254" type="siDrug">Pegaptanib sodium</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="2659" type="ciIndication"><TargetEntity id="1781" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1722" type="Action"><TargetEntity id="1103" type="Mechanism">VEGFR Inhibitors</TargetEntity><TargetEntity id="1619" type="Mechanism">Anti-VEGF</TargetEntity><TargetEntity id="1788" type="Mechanism">Vascular Endothelial Growth Factor (VEGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>77</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1722">VEGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15128">Ophthalmological agent</Class><Class id="1545">Anticancer</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="596">Injectable formulation</Technology><Technology id="103">Oligonucleotide</Technology><Technology id="620">Ophthalmic formulation</Technology><Technology id="348">PEGylated formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>317</PatientCountEnrollment><PatientCountEvaluable>207</PatientCountEvaluable><DateStart>2005-09-30T00:00:00Z</DateStart><DateEnd type="actual">2011-07-31T00:00:00Z</DateEnd><DateChangeLast>2018-11-19T08:37:40Z</DateChangeLast><DateAdded>2008-02-04T11:14:31Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Pfizer</Affiliation><Name>Pfizer Call Center</Name></Contact><Contact type="Public contact"><Affiliation>Westmead Millennium Institute for Medical Research</Affiliation><Name>Dr Paul Mitchell</Name></Contact><Contact type="Public contact"><Affiliation>University of Bonn in Germany</Affiliation><Name>Frank Holz</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Macular edema associated with diabetes&lt;/li&gt;&lt;li&gt;Visual acuity between 20/50 and 20/200&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Recent laser therapy in the eye&lt;/li&gt;&lt;li&gt;Recent signs of uncontrolled diabetes&lt;/li&gt;&lt;li&gt;Blood pressure worse
        than 160/100&lt;/li&gt;&lt;li&gt;Severe cardiac disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of participants with &gt;/= 10 letter (or two line) improvement in vision: refraction and best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts</Description><Timeframe>At baseline and year one</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of participants with a &gt;/= 10 letter (or two line) improvement in vision: refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts</Description><Timeframe>At baseline and year two</Timeframe></Measure><Measure><Description>Number of participants with a &gt;/= 15 letter (or two line) improvement in vision: refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts</Description><Timeframe>Baseline, one and two years</Timeframe></Measure><Measure><Description>Number of eyes with a two or more step increase in degree of retinopathy: retinopathy changes were monitored using fundus photography and fluorescein angiograph (FA) assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS final retinopathy severity scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where an increase in the step or retinopathy level indicated a worsening of the condition</Description><Timeframe>Baseline, one and two years</Timeframe></Measure><Measure><Description>Number of eyes with a two or more step decrease in degree of retinopathy: retinopathy changes were monitored using fundus photography and fluorescein angiograph (FA) assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS final retinopathy severity scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where a decrease in the step or retinopathy level indicated an improvement</Description><Timeframe>Baseline, one and two years</Timeframe></Measure><Measure><Description>Change from baseline in mean VA score: changes in VA monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS chart with participants at a 4-meter distance from chart. Distance VA expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 60, where higher ETDRS scores represented better vision. Change from baseline for each patient equaled (=) the visual acuity obtained at the observation minus the visual acuity at baseline</Description><Timeframe>Baseline, one and two years</Timeframe></Measure><Measure><Description>Number of participants requiring focal or grid laser treatment: included focal laser coagulation, focal laser photocoagulation, panretinal laser photocoagulation, retinal laser coagulation, and retinal laser photocoagulation</Description><Timeframe>At one and two years</Timeframe></Measure><Measure><Description>Number of Participants Requiring Focal or Grid Laser Treatment During Year 2: included focal laser coagulation, focal laser photocoagulation, panretinal laser photocoagulation, retinal laser coagulation, and retinal laser photocoagulation</Description><Timeframe>Two years </Timeframe></Measure><Measure><Description>Number of Participants Requiring Focal or Grid Laser Treatment During Year 1: included focal laser coagulation, focal laser photocoagulation, panretinal laser photocoagulation, retinal laser coagulation, and retinal laser photocoagulation</Description><Timeframe>One year </Timeframe></Measure><Measure><Description>Change From Baseline in Mean VA Score at two Years: changes in VA monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS chart with participants at a 4-meter distance from chart. Distance VA expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 60, where higher ETDRS scores represented better vision. Change from baseline for each patient equaled the visual acuity obtained at the observation minus the visual acuity at baseline</Description><Timeframe>Baseline, Year two</Timeframe></Measure><Measure><Description>Change From Baseline in Mean VA Score at one Year: changes in VA monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS chart with participants at a 4-meter distance from chart. Distance VA expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 60, where higher ETDRS scores represented better vision. Change from baseline for each patient equaled the visual acuity obtained at the observation minus the visual acuity at baseline</Description><Timeframe>Baseline, Year  one</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; was well tolerated with no new or unexpected safety signals. Adverse events  (AEs) were consistent with those observed in clinical trials of &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt;. The most frequent treatment-emergent AEs were conjunctival hemorrhage (22%), eye pain (10%), punctate keratitis (11%), and diabetic retinal edema (11%). Another common treatment-emergent AE, an increase in intraocular pressure related to the injection procedure was noted in 17 patients treated with &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; and in 7 patients treated with sham. Cardiac disorders were the most common, serious, treatment-emergent adverse events; these were reported in 6.9% of patients treated with &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; and 5.6% of patients treated with the sham procedure. There were no deaths related to the injection procedure or study drug [&lt;ulink linkType="Reference" linkID="1105941"&gt;1105941&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106057"&gt;1106057&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1199472"&gt;1199472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  purpose of the study was    to test whether &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; (pegaptanib sodium) injected into the eye, improves vision in
      more patients than the currently existing standard of care laser therapy.   The safety of
      Macugen compared to standard of care laser was also evaluated. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2010, results were published. The study met its primary endpoint of the proportion of patients gaining greater than ten letters versus sham at one year. At 54 weeks, 37% of patients given &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; gained two lines or ten letters on the ETDRS eye chart, compared with 20% of patients given sham injections (p = 0.0047). Patients in the &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; arm  gained an average of 5.2 letters of vision at one year, compared with 1.2 letters for patients receiving sham injections  (p &amp;lt; 0.05). At the end of two years, patients in the &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; group had gained an average of 6.1 letters, compared with 1.3 letters for patients in the sham arm (p &amp;lt; 0.01)  [&lt;ulink linkType="Reference" linkID="1105941"&gt;1105941&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106057"&gt;1106057&lt;/ulink&gt;]. In May 2011, similar results were presented.  &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; was found to be statistically superior to sham (P &amp;lt; 0.05) in terms of change in mean visual acuity scores (VAS) from baseline to 6, 24, 30, 36, 42, 54, 78, 84, 90, 96 and 102 weeks.   According to NEI-VFQ 25 questionnaire, there was a statistically and clinically significant difference between the &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; and sham group in terms of change from baseline in the domains of near vision activities, distance vision activities and social functioning at week 54. Also at week 102, the difference between the two groups in terms of composite score and the domains of distance vision activities, social functioning and mental health were statistically significant and clinically meaningful in favor of &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt;. According to EQ-5D questionnaire, there were no statistically significant differences between the two groups in terms of change in weighted index scores from baseline to week 54 or 102. Also, there was no statistically significant difference at both the time points in terms of change in VAS and AUC scores [&lt;ulink linkType="Reference" linkID="1180906"&gt;1180906&lt;/ulink&gt;]. Similar results were presented in June 2011. At week 54, 23.3 and 41.7% of patients treated with &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; and sham respectively (p = 0.002), received  focal/grid laser treatment; while at week 102,  25.2 and 45% of patients treated with &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; and sham respectively (p = 0.003), received  focal/grid laser treatment [&lt;ulink linkType="Reference" linkID="1199472"&gt;1199472&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Results were published in September, 2011. From baseline to week 54, &gt;/= 10 letter gains seen in 36.8% of pegaptanib and 19.7% of sham-treated subjects (p = 0.0047). The VA trend favored pegaptanib, at two years. Statistically significant (p &amp;lt; 0.05) benefits favoring pegaptanib were the NEI-VFQ 25 domains of Near Vision, Distance Vision, and Social Functioning (week 54) and Distance Vision, Social Functioning, Mental Health, and Composite Score (week 102) demonstrated clinically meaningful (&gt; 5-point between-group difference). There was no significant difference in the mean change in generic EQ-5D-weighted utility scores [&lt;ulink linkType="Reference" linkID="1546661"&gt;1546661&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive intravitreal injection of Macugen 0.3 mg/90 microl every 6 weeks up to two years or   standard of care (clinicians decision to use optional laser therapy).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized in a 1 : 1 ratio to receive either  0.3 mg/90 microl of &lt;ulink linkType="Drug" linkID="17475"&gt;Macugen&lt;/ulink&gt; injection or a sham procedure every 6 weeks for a total of nine injections in the year one and in the year two, patients received injections as often as every 6 weeks based on pre-specified criteria, including visual acuity, clinical examination and optical coherence tomography (OCT). Up to three focal or grid laser treatments per year were permitted beginning at week 18. Patients were provided with an option  to be enrolled in an open-label three-year extension   study [&lt;ulink linkType="Reference" linkID="1105941"&gt;1105941&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106057"&gt;1106057&lt;/ulink&gt;],   [&lt;ulink linkType="Reference" linkID="1180906"&gt;1180906&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="1199472"&gt;1199472&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>pegaptanib</Name><Drug id="17475">pegaptanib</Drug><Dose unit="milligram dose">0.3</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="1145">Keratitis</Indication><CountPatientsAffectedPercentage>11.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="20">Pain</Indication><CountPatientsAffectedPercentage>10.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2522">Ocular hemorrhage</Indication><CountPatientsAffectedPercentage>22.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2659">Diabetic macular edema</Indication><CountPatientsAffectedPercentage>11.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="6742">pegaptanib</Intervention><Treatments><Treatment><Dose>0.3 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Innsbruck</Address1><Address3>A-6020</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Wien</Address1><Address3>A-1180</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Innsbruck</Address1><Address3> A6020</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Wien</Address1><Address3> A-1180</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Australia"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>East Melbourne</Address1><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Westmead</Address1><Address2>New South Wales</Address2><Address3>2145</Address3><CountrySubDivision>New South Wales</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Westmead</Address1><Address3> 2145</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Belgium"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Brazil"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Gioania</Address1><Address2>GO</Address2><Address3>74210-010</Address3><CountrySubDivision>GO</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Porto Alegre</Address1><Address3>90035-003</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Sao Paolo</Address1><Address3>SP 04524-20</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Sao Paulo</Address1><Address3>04524-020</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Gioania</Address1><Address3> 74210-010</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Porto Alegre</Address1><Address3> 90035003</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Sao Paolo</Address1><Address3> SP 04524-20</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H1T 2H1</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><Address3>V5Z 3N9</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Montreal</Address1><Address3> H1T 2H1</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Vancouver</Address1><Address3> V5Z 3N9</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Switzerland"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Bern</Address1><Address3>CH-3010</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Bern</Address1><Address3> CH3010</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Colombia"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Bogota</Address1><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Czech Republic"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Brno</Address1><Address3> 625 00</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Hradec Kralove</Address1><Address3> 500 05</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Olomouc</Address1><Address3> 775 20</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Praha 4</Address1><Address3> 140 00</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Praha 6</Address1><Address3> 169 00</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Bonn</Address1><Address3>53105</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Duesseldorf</Address1><Address3>40225</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Heidelberg</Address1><Address3>69120</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Leipzig</Address1><Address3>04103</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Muenster</Address1><Address3>48145</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tuebingen</Address1><Address3>72706</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Bonn</Address1><Address3> 53105</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Duesseldorf</Address1><Address3> 40225</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Heidelberg</Address1><Address3> 69120</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Leipzig</Address1><Address3> 4103</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Munster</Address1><Address3> 48145</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tubingen</Address1><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tuebingen</Address1><Address3> 72706</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Denmark"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Glostrup</Address1><Address3>2600</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Glostrup</Address1><Address3> 2600</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Clermont</Address1><Address3>63003</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Creteil</Address1><Address2>Cedex</Address2><Address3>94010</Address3><CountrySubDivision>Cedex</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Lyon</Address1><Address3>69006</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Marseille</Address1><Address3>13008</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Marseille Cedex 5</Address1><Address3>13385</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Marsielle</Address1><Address3>13008</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Nancy Cedex</Address1><Address3>54035</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Paris Cedex 12</Address1><Address3>75571</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Clermont</Address1><Address3> 63003</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Creteil</Address1><Address3> 94010</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Lyon</Address1><Address3> 69006</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Marseille Cedex 5</Address1><Address3> 13385</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Marseille</Address1><Address3> 13 008</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Nancy Cedex</Address1><Address3> 54035</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Paris Cedex 12</Address1><Address3> 75571</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Newcastle Upon Tyne</Address1><Address3>NE1 4LP</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Sheffield</Address1><Address3>S10 2JF</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Newcastle Upon Tyne</Address1><Address3> NE1 4LP</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Newcastle Upon Tyne</Address1><Address3> NE1 4LP</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Sheffield</Address1><Address3> S10 2JF</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Sheffield</Address1><Address3> S10 2JF</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Greece"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Athens</Address1><Address3>12462</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Athens</Address1><Address3> 124 62</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="India"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Ahmedabad</Address1><Address3>380 004</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Bangalore</Address1><Address3>560 085</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Hyderabad</Address1><Address3>500 034</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>New Delhi</Address1><Address3>110 029</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Ahmedabad</Address1><Address3> 380 004</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Bangalore</Address1><Address3> 560 085</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Hyderabad</Address1><Address3> 500 034</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>New Delhi</Address1><Address3> 110 029</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Firenze</Address1><Address3>50134</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Milano</Address1><Address3>20132</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Udine</Address1><Address3>33100</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Firenze</Address1><Address3> 50134</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Milano</Address1><Address3> 20132</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Udine</Address1><Address3> 33100</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Nijmegen</Address1><Address3>6500</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Nijmegen</Address1><Address3> 6500</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Portugal"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Coimbra</Address1><Address3>3000-354</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Coimbra</Address1><Address3> 3000-354</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>'Aiea</Address1><Address2>Hawaii</Address2><Address3>96701</Address3><CountrySubDivision code="HI">Hawaii</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Abilene</Address1><Address2>Texas</Address2><Address3>79606</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Augusta</Address1><Address2>Georgia</Address2><Address3>30909</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><Address3>28210</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3>80230</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><Address3>48201-1423</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Fort Lauderdale</Address1><Address2>Florida</Address2><Address3>33334-4146</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><Address3>76104</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Hamden</Address1><Address2>Connecticut</Address2><Address3>06518</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77002</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3>46280</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90095</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Lynbrook</Address1><Address2>New York</Address2><Address3>11563</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>McAllen</Address1><Address2>Texas</Address2><Address3>78503</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3>53226</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Oakland</Address1><Address2>California</Address2><Address3>94609</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85020</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><Address3>15213</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78240</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Santa Ana</Address1><Address2>California</Address2><Address3>92705</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33609</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Temple</Address1><Address2>Texas</Address2><Address3>76508</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85704</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>West Columbia</Address1><Address2>South Carolina</Address2><Address3>29169</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67214</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Abilene</Address1><Address2>Texas</Address2><Address3> 79606</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Aiea</Address1><Address2>Hawaii</Address2><Address3> 96701</Address3><CountrySubDivision code="HI">Hawaii</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Augusta</Address1><Address2>Georgia</Address2><Address3> 30909</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3> 2114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><Address3> 28210</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3> 80230</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><Address3> 48201-1423</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Fort Lauderdale</Address1><Address2>Florida</Address2><Address3> 33334-4146</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><Address3> 76104</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Hamden</Address1><Address2>Connecticut</Address2><Address3> 6518</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3> 77002</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3> 46280</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3> 46280-2301</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3> 90095</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Lynbrook</Address1><Address2>New York</Address2><Address3> 11563</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>McAllen</Address1><Address2>Texas</Address2><Address3> 78503</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3> 53226</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Nyc</Address1><Address2>New York</Address2><Address3> 10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Oakland</Address1><Address2>California</Address2><Address3> 94609</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3> 85020</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><Address3> 15213</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Rockville Centre</Address1><Address2>New York</Address2><Address3> 11570</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3> 78240</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Santa Ana</Address1><Address2>California</Address2><Address3> 92705</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tampa, Florida</Address1><Address2>Florida</Address2><Address3> 33609</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3> 33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Temple</Address1><Address2>Texas</Address2><Address3> 76508</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3> 85704</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>West Columbia</Address1><Address2>South Carolina</Address2><Address3> 29169</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3> 67214</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="South Africa"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Bloemfontein</Address1><Address3>9301</Address3><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Bloemfontein</Address1><Address3> 9301</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Brno</Address1><Address2>Czechia</Address2><Address3>625 00</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Hradec Kralove</Address1><Address2>Czechia</Address2><Address3>50005</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Olomouc</Address1><Address2>Czechia</Address2><Address3>775 20</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Praha 4</Address1><Address2>Czechia</Address2><Address3>140 00</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pfizer Investigational Site</Name><Address1>Praha 6</Address1><Address2>Czechia</Address2><Address3>169 00</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="115">Subjects with diabetic retinopathy</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Diabetic complication</Disease><PatientSegments><PatientSegment><PatientSegment id="8454">Subjects with Diabetic Macular Edema</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Macular edema</Disease><PatientSegments><PatientSegment><PatientSegment id="9522">Subjects with Diabetic Macular Edema(DME)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18886">Subjects with Protocol Specified Vision Loss</PatientSegment><SubSegments><SubSegment id="9534">Subjects with Mild Vision Loss</SubSegment><SubSegment id="9535">Subjects with Moderate Vision Loss</SubSegment><SubSegment id="9536">Subjects with Severe Vision Loss</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT Alias">NCT00148811</Identifier><Identifier type="NCT">NCT00605280</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Diabetic complication" id="11294"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Macular edema" id="16429"><Endpoint>Assessment of Visual Function</Endpoint><SubEndpoints><SubEndpoint disease="Macular edema" id="16430">Assessment of visual acuity(VA)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Diabetic complication" id="11294"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Macular edema" id="16429"><Endpoint>Assessment of Visual Function</Endpoint><SubEndpoints><SubEndpoint disease="Macular edema" id="16430">Assessment of visual acuity(VA)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="587"><Criterion>Subjects with Diabetic Complications</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="589">Subjects with diabetic retinopathy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Macular edema" id="15410"><Criterion>Subjects with Diabetic Macular Edema(DME)</Criterion></Inclusion><Inclusion disease="Macular edema" id="33800"><Criterion>Subjects with Protocol Specified Vision levels</Criterion><SubCriteria><SubCriterion disease="Macular edema" id="15421">Subjects with mild vision loss</SubCriterion><SubCriterion disease="Macular edema" id="15422">Subjects with moderate vision loss</SubCriterion><SubCriterion disease="Macular edema" id="15423">Subjects with severe vision loss</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diabetic complication" id="35047"><Criterion>Subjects with Diabetic Complications</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="6972">Subjects with Diabetic Macular Edema</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="855"><Criterion>Subjects with Diabetic Complications</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="885"><Criterion>Subjects co-morbid with hypertension</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="889">Subjects co-morbid with uncontrolled/untreated hypertension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="891"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="907"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Diabetic complication" id="8512"><Criterion>Subjects with Diabetic Complications</Criterion></Exclusion><Exclusion disease="Diabetic complication" id="8541"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Diabetic complication" id="8556"><Criterion>Subjects co-morbid with hypertension</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8560">Subjects co-morbid with uncontrolled/untreated hypertension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="8583"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Macular edema" id="14045"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Macular edema" id="14046">Subjects co-morbid with ocular conditions with risk of macular edema</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Macular edema" id="14048"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Macular edema" id="14063"><Criterion>Subjects with History of/Scheduled for Ocular Therapy</Criterion><SubCriteria><SubCriterion disease="Macular edema" id="14065">Subjects with history of/scheduled for ocular procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="23191"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1581">Ocular surgeries/ Interventions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="23193"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8605">Ocular surgeries/ Interventions</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-11-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>54.06 Months</EnrollmentPeriod><EnrollmentRate>5.86 Patients/Month</EnrollmentRate><DateFirstReceived>2008-01-18T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-02-04T11:14:31Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="80763"><TitleDisplay>Pomalidomide in Combination With High-Dose Dexamethasone and Oral Cyclophosphamide</TitleDisplay><TitleOfficial>Evaluation of Pomalidomide in Combination With High-Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MCC-16705</Identifier><Identifier type="NCT">NCT01432600</Identifier><Identifier type="Secondary Organisational">PO-MM-PI-0039</Identifier></Identifiers><Indications><Indication id="1828">Multiple myeloma</Indication></Indications><BiomarkerNames><BiomarkerName id="749" role="Disease marker" type="Proteomic">Free light chains</BiomarkerName><BiomarkerName id="8322" role="Disease marker" type="Proteomic">Free light chain ratio</BiomarkerName><BiomarkerName id="13158" role="Disease marker" type="Proteomic">Myeloma protein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>dexamethasone</Name></Intervention><Intervention type="InterventionPrimary"><Name>pomalidomide</Name><Drug id="27696">pomalidomide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="27696">pomalidomide</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="15331">Celgene Corp</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="27696" type="Drug"><TargetEntity id="269739" type="siDrug">Pomalidomide</TargetEntity></SourceEntity><SourceEntity id="15331" type="Company"><TargetEntity id="4295905897" type="organizationId">Celgene Corp</TargetEntity></SourceEntity><SourceEntity id="29603" type="Company"><TargetEntity id="4298207159" type="organizationId">H Lee Moffitt Cancer Center and Research Institute Inc</TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company></CompaniesSponsor><CompaniesCollaborator><Company id="15331">Celgene Corp</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="1545">Anticancer</Class><Class id="1596">Immunomodulator</Class><Class id="382">TNF alpha synthesis inhibitor</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>80</PatientCountEnrollment><PatientCountEvaluable>82</PatientCountEvaluable><DateStart>2011-11-30T00:00:00Z</DateStart><DateEnd type="actual">2016-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:18:09Z</DateChangeLast><DateAdded>2011-09-16T10:15:46Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of California, San Francisco</Affiliation><Name>Weiyun Ai</Name></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute</Affiliation><Name>Melissa Alsina</Name></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute</Affiliation><Name>Charalambos Andreadis</Name></Contact><Contact type="Public contact"><Affiliation>University of California San Francisco</Affiliation><Name>Wanda Boyer</Name></Contact><Contact type="Public contact"><Affiliation>Mount Sinai School of Medicine, The Tisch Cancer Institute</Affiliation><Name>Arlynn Brion</Name></Contact><Contact type="Public contact"><Affiliation>Mount Sinai School of Medicine, The Tisch Cancer Institute</Affiliation><Name>Hearn Cho</Name></Contact><Contact type="Public contact"><Affiliation>University of California San Francisco</Affiliation><Name>Lloyd Damon</Name></Contact><Contact type="Public contact"><Affiliation>Mount Sinai School of Medicine, The Tisch Cancer Institute</Affiliation><Name>Denise Dea</Name></Contact><Contact type="Public contact"><Affiliation>Mount Sinai School of Medicine, The Tisch Cancer Institute</Affiliation><Name>Sundar Jagannath</Name></Contact><Contact type="Public contact"><Affiliation>Site 513; Buffalo; New York</Affiliation><Email>dubovsky@buffalo.edu</Email><Name>Steven Dubovsky</Name><Phone>Site 513; Buffalo; New York</Phone></Contact><Contact type="Public contact"><Affiliation>University of California San Francisco</Affiliation><Name>Karin Gaensler</Name></Contact><Contact type="Public contact"><Affiliation>University of California Med. Center; San Francisco</Affiliation><Name>Lawrence Kaplan</Name></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute</Affiliation><Name>Amit Mahipal</Name></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute</Affiliation><Name>Lisa Nardelli</Name></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute</Affiliation><Name>Taiga Nishihori</Name></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute</Affiliation><Name>Jose Ochoa-Bayona</Name></Contact><Contact type="Public contact"><Affiliation>University of California San Francisco</Affiliation><Name>Tom Martin</Name></Contact><Contact type="Public contact"><Affiliation>University of California Med. Center; San Francisco</Affiliation><Name>Rebecca Olin</Name></Contact><Contact type="Public contact"><Affiliation>University of California Med. Center; San Francisco</Affiliation><Name>Catherine Smith</Name></Contact><Contact type="Public contact"><Affiliation>Mount Sinai School of Medicine, The Tisch Cancer Institute</Affiliation><Name>Keren Osman</Name></Contact><Contact type="Public contact"><Affiliation>University of California, San Francisco</Affiliation><Name>Geraldine Pelle-day</Name></Contact><Contact type="Public contact"><Affiliation>University of California, San Francisco</Affiliation><Name>Neil Shah</Name></Contact><Contact type="Public contact"><Affiliation>University of California, San Francisco</Affiliation><Name>Jeffrey Venstrom</Name></Contact><Contact type="Public contact"><Affiliation>University of California, San Francisco</Affiliation><Name>Jeffrey Wolf</Name></Contact><Contact type="Public contact"><Affiliation>H.  Lee Moffitt Cancer Center and Research Institute</Affiliation><Name>Daniel Sullivan</Name></Contact><Contact type="Scientific contact"><Affiliation>H. Lee Moffitt Cancer and Research Institute</Affiliation><Name>Rachid Baz, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have relapsed or refractory multiple myeloma. Refractory disease is
             defined as patients who experience disease progression on active therapy or within 60
             days after the discontinuation of therapy. Relapsed disease is defined as achievement
             of at least a partial response followed by disease progression after 60 days of
             discontinuing active therapy&lt;/li&gt;&lt;li&gt;Must have measurable disease as assessed by one of the following criteria:&lt;ul&gt;&lt;li&gt;Serum
             monoclonal protein &gt;/=  0.5 g/dl by protein electrophoresis&lt;/li&gt;&lt;li&gt;Has &gt; 200 mg of monoclonal
             protein in the urine on 24 h electrophoresis&lt;/li&gt;&lt;li&gt;Serum immunoglobulin free light
             chain &gt;/=  10 mg/dl&lt;/li&gt;&lt;li&gt;Abnormal serum immunoglobulin kappa to lambda free light chain
             ratio&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Must have received at least two prior therapies to include prior immunomodulatory drug
             (lenalidomide) and the patient must be refractory to lenalidomide (defined as
             progressive disease during active therapy or within 60 days of discontinuation of
             therapy). All previous cancer chemotherapy (bisphosphonates are not included),
             including surgery, must have been discontinued &gt;/= 2 weeks prior to first dose of study
             drug. Prior radiotherapy must have been completed &amp;gt; 2 weeks prior to the start of
             study drug unless the radiation field would not impact marrow reserve in the opinion
             of the investigator&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status&amp;lt;/= 2 (Karnofsky &gt;/= 60%)
&lt;/li&gt;&lt;li&gt;  Must have acceptable organ function:&lt;ul&gt;&lt;li&gt;Total bilirubin&amp;lt; 1.5 mg/dl&lt;/li&gt;&lt;li&gt;Aspartic
             transaminase (AST), serum glutamic oxaloacetic transaminase (SGOT)/alanine transaminase
             (ALT), serum glutamic pyruvic transaminase (SGPT) &amp;lt;/= 2.5 x  institutional upper limit of
             normal (ULN)&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt; 3 mg/dl
&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients must have adequate hematological function as evidenced by the following:&lt;ul&gt;&lt;li&gt;For the Phase I study: absolute neutrophil count (ANC) &gt;/=  1000/mm3; platelet count &gt;/= 50,000/mm3&lt;/li&gt;&lt;li&gt;For the phase II portion, patients with &gt; 50% bone marrow plasmacytosis will be
        allowed to enter the trial if the platelet count is &gt; 30,000/mm3 and
        regardless of baseline absolute neutrophil count if it is felt to be related to active
        myeloma and if in the opinion of the investigator, growth factor support can result in
        improvement in the neutrophil count to &gt; 1000/mm3 growth factor can be used during screening)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Females of childbearing potential (FCBP) must have a negative serum or urine
             pregnancy test with a sensitivity of at least 25 mIU/ml within 10 to 14 days prior to
             and again within 24 h of starting pomalidomide and must either commit to
             continued abstinence from heterosexual intercourse or begin two acceptable methods of
             birth control, one highly effective method and one additional effective method at  the same time, at least 28 days before she starts taking pomalidomide. FCBP must also
             agree to ongoing pregnancy testing. Men must agree to use a latex condom during
             sexual contact with a FCBP even if they have had a vasectomy&lt;/li&gt;&lt;li&gt;Ability to understand and the willingness to sign a written informed consent document&lt;/li&gt;&lt;li&gt;Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
             intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)&lt;/li&gt;&lt;li&gt;All study patients must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who have had chemotherapy or radiotherapy within 2 weeks (see above or those
             who have not recovered from adverse events due to agents administered more than 2
             weeks earlier [except for neuropathy])&lt;/li&gt;&lt;li&gt;Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the patient from signing the informed consent form&lt;/li&gt;&lt;li&gt;Any condition, including the presence of laboratory abnormalities, which places the
             patient at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study. Use of any other experimental drug or
             therapy within 28 days of baseline&lt;/li&gt;&lt;li&gt;Known hypersensitivity to thalidomide or lenalidomide&lt;/li&gt;&lt;li&gt;The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide, pomalidomide or similar drugs&lt;/li&gt;&lt;li&gt;Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type
             A, B or C&lt;/li&gt;&lt;li&gt;May not be receiving any other investigational agents&lt;/li&gt;&lt;li&gt;Pregnant or breast feeding females (lactating females must agree not to breast feed
             while taking pomalidomide)&lt;/li&gt;&lt;li&gt;Patients with prior pomalidomide therapy (greater than one cycle) are excluded&lt;/li&gt;&lt;li&gt;Another active malignancy requiring treatment within the next 12 months, with the
             exception of basal cell skin cancer, in situ cervical cancer, in situ breast cancer
             and asymptomatic prostate cancer
&lt;/li&gt;&lt;li&gt;Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection (except simple urinary tract or upper respiratory tract infection),
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,
             or psychiatric illness/social situations that would limit compliance with study
             requirements&lt;/li&gt;&lt;li&gt;Inability to comply with the protocol requirements or participation in any other
             clinical study&lt;/li&gt;&lt;li&gt;Corticosteroid therapies of&amp;gt; 20 mg/day prednisone, &amp;gt; 4 mg/day dexamethasone, &amp;gt; 80
             mg/day hydrocortisone, or equivalent&lt;/li&gt;&lt;li&gt;Allogeneic stem cell/bone marrow transplant within 12 months of first dose of study
             drug or active graft versus host disease&lt;/li&gt;&lt;li&gt;Patients with existing peripheral neuropathy grade&amp;gt; 2&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Phase I - maximum tolerated dose (MTD): the maximum tolerated dose of oral weekly cyclophosphamide in milligrams (mg), in combination with pomalidomide and dexamethasone. Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows: Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg. The period for assessment of Dose Limiting Toxicity (DLT) is the first cycle (28 days). The following toxicities will be considered dose limiting if encountered only in the phase I portion of the study: Febrile neutropenia; Grade 3 or 4 non-hematologic toxicity related to treatment with pomalidomide or cyclophosphamide; Participants must have received optimal symptomatic treatment for Grade 3 or 4 nausea, vomiting, or diarrhea to be considered a DLT; Grade 4 transaminitis; Grade 3 transaminitis must be present for&gt;/= 7 days to be considered a DLT; Grade 4 thrombocytopenia for 7 or more days; Grade 4 neutropenia for 7 or more day</Description><Timeframe>28 days</Timeframe></Measure><Measure><Description>Phase II - Overall Response Rate (ORR): overall response, Minimal Remission (MR) or better per treatment arm, using the uniform response criteria by the International Myeloma Working Group (IMWG) of pomalidomide in combination with high dose dexamethasone with or without cyclophosphamide in participants with relapsed and refractory myeloma. In addition, Minimal response was incorporated in those response criteria as this is a valid endpoint in patients with relapsed or refractory myeloma. MR: 25-49% reduction in serum paraprotein and a 50 to 89% reduction in urine light chain excretion; A 25 to 49% reduction in the size of soft tissue plasmacytoma must be demonstrated is applicable</Description><Timeframe>24 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Phase II - Median progression-free survival (PFS): progression free survival per treatment arm. Progressive Disease (PD) requires one of the following, increase of greater than or equal to 25% from baseline in: Serum M-component; Urine M-component; The difference between involved and uninvolved sFLC levels; The size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia</Description><Timeframe>24 months</Timeframe></Measure><Measure><Description>Phase II - Median  overall survival (OS): overall survival per treatment arm. Overall survival is defined as the time from start of treatment to death of any cause</Description><Timeframe>24 months</Timeframe></Measure><Measure><Description>Phase II - Occurrence of Possibly Related Adverse Events (AEs): phase II: Participants with Grade 3 or 4 adverse events at least possibly related to the study treatment in 5% of participants in the Phase 2 portion, by AE category, assessed by the National Cancer Institute Common Terminology Criteria (NCI CTC) version 4.0</Description><Timeframe>24 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In December 2012, results were presented. During cycle 1, another patient with a history of colitis had a flare of his colitis which required iv antibiotics. In dose level 2, a VGPR was observed in one patient, partial remission (PR) in two, MR in one and stable disease (SD) in two. Dexamethasone dose reductions were seen in 6/10 patients. Pomalidomide or cyclophosphamide dose reductions were not observed. Grade 3/4 neutropenia, and thrombocytopenia were observed in 5 (50%), 3 (30%) patients. Febrile neutropenia was observed in one patient  [&lt;ulink linkType="Reference" linkID="1516279"&gt;1516279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, results were published. Toxicity was predominantly hematologic in nature but was not statistically higher in arm B [&lt;ulink linkType="Reference" linkID="1783912"&gt;1783912&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main purpose of this study was to see whether &lt;ulink linkType="Drug" linkID="27696"&gt;pomalidomide&lt;/ulink&gt; could help people with myeloma and also  to find out if pomalidomide was safe and tolerable.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2012, results were presented. In dose level 1,  In dose level 1, Dose limiting toxicity (DLT) was not observed and a very good partial remission (VGPR) was achieved by one patient and one a MR. In dose level 2, an upper extremity DVT (DLT) was observed in one patient, diverticular rupture was observed in one patient in cycle 2 [&lt;ulink linkType="Reference" linkID="1516279"&gt;1516279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, results were published. The ORR was 38.9 and 64.7% for arms A and B, respectively (p = 0.035). A total of 62/70 patients had progressed. The median progression-free survival (PFS) was 4.4 and 9.5 months for arms A and B, respectively (p = 0.106) [&lt;ulink linkType="Reference" linkID="1783912"&gt;1783912&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;There would be two parts to this study: &lt;br/&gt;Phase I: to determine a safe dose of the medication
           cyclophosphamide in combination with pomalidomide and dexamethasone.&lt;br/&gt;Phase II:   would look to see the
           difference in effectiveness of pomalidomide in combination with high dose dexamethasone
           with or without cyclophosphamide for the treatment of patients who have myeloma, which
           has relapsed to or become refractory (not responding) to prior treatment.&lt;/para&gt;&lt;para&gt;Phase  I: patients would receive pomalidomide (4 mg po on days 1 to 21 of a 28-day cycle) in combination with high-dose dexamethasone (40 mg po on days 1 to 4, 15 to 19 of a 28-day cycle for the first four cycles and subsequently 40 mg po on days 1, 8, 15, and 22) and cyclophosphamide (up to 500 mg po on days 1, 8, and 15).&lt;/para&gt;&lt;para&gt;Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators  would proceed with the second phase of the trial which would be a randomized phase II study comparing pomalidomide and dexamethasone and pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.&lt;/para&gt;&lt;para&gt;Phase II (arm A): patients would receive pomalidomide (4 mg po on days 1 to 21 of a 28 days cycle)  in combination with high-dose dexamethasone (40 mg po on days on days 1, 8, 15, and 22).&lt;br/&gt;Phase II (arm B): patients would receive pomalidomide (4 mg po on days 1 to 21 of a 28 days cycle) In combination with high-dose dexamethasone  (40 mg po on days on days 1, 8, 15, and 22) and  cyclophosphamide (400 mg po on days 1, 8, and 15).&lt;/para&gt;&lt;para&gt;Patients &amp;gt; 75 years of age, would receive 20 mg of dexamethasone instead of 40 mg of dexamethasone on the schedules noted above given the impaired tolerance for this age group to high-dose dexamethason.  Aspirin (81 mg po daily) would be given during the course of treatment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were treated with &lt;ulink linkType="Drug" linkID="27696"&gt;pomalidomide&lt;/ulink&gt; 4 mg po days 1 to 21, dexamethasone 40 mg po on days 1 to 4; 15 to 19 (20 mg if &amp;gt;  75 years) and oral cyclophosphamide on days 1, 8, 15 of a 28 days cycle. Three cyclophosphamide dose levels (300, 400 and 500 mg) were planned in this dose-escalation  [&lt;ulink linkType="Reference" linkID="1516279"&gt;1516279&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1783912"&gt;1783912&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="198131">cyclophosphamide</Intervention><Treatments><Treatment><Dose>300 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>400 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>500 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="198130">dexamethasone</Intervention><Treatments><Treatment><Dose>40 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="198129">pomalidomide</Intervention><Treatments><Treatment><Dose>4 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>H. Lee Moffitt Cancer Center and Research Institute</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mount Sinai School of Medicine, The Tisch Cancer Institute</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10029-6574</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of California San Francisco</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94143</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Multiple myeloma</Disease><PatientSegments><PatientSegment><PatientSegment id="3923">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3926">Subjects with Relapsed/Recurrent Multiple Myeloma</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01432600</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Multiple myeloma" id="7391"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="9342">Assessment of Disease Response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Multiple myeloma" id="7520"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Multiple myeloma" id="7354"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7360"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7488"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7489">Assessment of other adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Multiple myeloma" id="4627"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4628">Subjects with measurable serum M-protein</SubCriterion><SubCriterion disease="Multiple myeloma" id="4629">Subjects with measurable urine M-protein</SubCriterion><SubCriterion disease="Multiple myeloma" id="5227">Subjects with measurable serum/urine immunoglobulins</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4658"><Criterion>Subjects with Acceptable Myeloma Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4663">Subjects with acceptable serum light chain levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4690"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4691">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Multiple myeloma" id="4692">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Multiple myeloma" id="4693">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion><SubCriterion disease="Multiple myeloma" id="4697">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4711"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4717">Patient with history of immunotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4738"><Criterion>Subjects with Response to Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4740">Subjects with partial response (pR) to MM therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4756"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Multiple myeloma" id="4767"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Multiple myeloma" id="5228"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4672">Subjects with acceptable hematological status</SubCriterion><SubCriterion disease="Multiple myeloma" id="4675">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="33354"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4712">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Multiple myeloma" id="4720">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="34054"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4676">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Multiple myeloma" id="6065"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6082"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6086"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6107"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6108">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="6124"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6125">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Multiple myeloma" id="6133">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Multiple myeloma" id="6134">Subjects with history of stem cell therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="6144"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-08-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>28.06 Months</EnrollmentPeriod><EnrollmentRate>2.85 Patients/Month</EnrollmentRate><DateFirstReceived>2011-09-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-09-16T10:15:46Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-01-17T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2014-04-09T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-09-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>